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Chapter 1 
 
General introduction 
 
1.1. Preface 
 
Almost all chemical reactions including post-translational modification of proteins in 
living organisms are catalyzed by enzymes, and enzymes play a significant role in many 
physiological processes such as signaling, metabolism, and gene regulation. There are 
thousands of enzymes in living body, and enzymes are known to play a fundamental role 
in the pathology of several major human diseases. Therefore, the detection of disease-
related enzymes in living samples is essential for research in biology and medicine, and 
many techniques for enzyme assay have been intensely developed. Herein, we focus on 
proteases defined as hydrolase, and provide a concise but general background of proteases 
and protease assays. 
 
1.2. Protease 
 
Proteases, which are some of the most vital physiological enzymes, have been targeted 
for the development of simple and sensitive assays for disease diagnosis, therapy, and 
biological research. Proteases hydrolyze the amide bond at specific sites of the 
polypeptide chain, and play key roles in the regulation of a large number of physiological 
processes such as cell proliferation and differentiation, apoptosis, DNA replication, 
hemostasis (coagulation), and immune responses.1,2  
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For instance, caspases, which are one of cysteine proteases, play a critical role in cell 
regulation such as controlling inflammation and cell death, and dysregulation of caspases 
is involved in human diseases such as cancer, degenerative disease, and inflammatory 
disorders.3−5 Cathepsins, digestive and regulatory proteases, also participate in many 
physiological processes such as antigen presentation in immune system, collagen 
turnover in bone and cartilage, and neuropeptide and hormone processing.6 Cathepsins 
are associated with various human diseases including cancer, arthritis, and 
osteoporosis.7−10 Human immunodeficiency virus (HIV)-1 protease is essential for the 
maturation of HIV, and the detection and inhibition of HIV-1 protease in the HIV life 
cycle are required for diagnosis and therapy of acquired immunodeficiency syndrome 
(AIDS).11−13  
 
As stated above, proteases have key roles in multiple physiological and pathological 
processes, and have potential for promising drug targets or diagnostic and prognostic 
biomarkers.14 Therefore, various approaches for protease assay have been enthusiastically 
studied and developed due to the significance of protease detection. 
 
1.3. Immunology-based method 
 
Immunological detection methods for protease, which utilize antigen-antibody reaction, 
can quantify a desired protease in even complicated samples derived from living body 
because the antigen-antibody reaction is specific and sensitive. Western blot and enzyme-
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linked immuno-sorbent assay (ELISA) methods are widely used for qualification of 
proteins including protease.15  
 
Western blotting, which was reported by Burnette in 1981, is a method that sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) technique is combined 
with antigen-antibody reaction.16 After completion of the electrophoresis, a replica of the 
separated proteins can be made onto an adsorbent such as polyvinylidenefluoride (PVDF) 
or nitrocellulose (Fig. 1).17 Subsequently, primary antibody is bound to a specific band 
on the blot, and secondary antibody conjugated to an enzyme such as alkaline phosphatase 
or horse radish peroxidase is bound to the primary antibody. Finally, color of specific 
band is developed and measured to detect target protease. 
 
 
Fig. 1  Schematic representation of western blotting and detection procedure.18 
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ELISA, which was reported by Engvall and Perlmann in 1971, is a technique that the 
specificity of antibodies is combined with the sensitivity of simple enzyme assays by 
using antibodies or antigens coupled to an enzyme which can be readily assayed.19 
Although many variants of ELISA test procedures have been developed to date, 
sandwich-ELISA is the most common kind.20,21 In sandwich-ELISA, the amount of target 
protease (antigen) between two layers of antibodies which are consisted of immobilized 
or labelled antibodies respectively is measured (Fig. 2). Antigen-specific antibody is 
immobilized on the well of microplate. Antigen binds to immobilized antibody when 
adding antigen. Next, enzyme-labelled antibody is added, and bound to antigen-
conjugated immobilized antibody. Finally, the chromogenic or fluorogenic substrates for 
the detection of labelled enzyme are added, and the colored product is measured to detect 
the target protease. 
 
 
Fig. 2  Schematic representation of sandwich-ELISA protocol.21 
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However, immunological methods cannot be used for the detection of protease activity 
because these methods are focused on quantitating the amount of protease.22 
Measurement of the protease activity is significant because the disease states are directly 
related to protease activity rather than protease quantity. For example, prion disease is 
relevant to several protease activities. Prion disease is a group of human and animal 
neurodegenerative disorders, and results from the conversion of a normal cell-surface 
glycoprotein (PrPC) with a primarily α-helical structure into conformationally altered 
pathogenic isoform (PrPSc) which is β-sheet rich.23,24 PrPSc has partial resistance to 
proteolysis,25 and is an essential component of proteinaceous infectious particles 
(prions).26 PrPC is shed at plasma membrane by metalloprotease ADAM10, and the shed 
PrPC may impact on prion disease.27 The prion-related proteins are subject to proteolytic 
processing, and these cleavages are potentially involved in progression of prion disease.28 
Porphyromonas gingivalis, which is one of the major pathogens of periodontitis, secretes 
cysteine proteases gingipains.29,30 Gingipain activities are implicated in infection, 
acquisition of nutrients, evasion of antibacterial defenses, and tissue invasion and 
dissemination.31 Therefore, gingipain activities are directly involved in pathological 
events during development and progression of periodontitis.32 According to these 
findings, protease activity is intimately correlated to progression and state of diseases, 
and measuring protease activity is meaningful in terms of disease diagnosis, 
pathophysiological research, and drug discovery. Moreover, evaluation of protease 
inhibitors cannot be performed by the immunological techniques. Inhibitor evaluation is 
considered as a valuable work by medicinal chemists and pharmacologists because it is 
necessary in drug discovery. Besides, the immnological assays are time consuming, and 
required expensive reagents and specific instruments.33,34 To overcome the limitations in 
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these immunological assays, optical methods using chromogenic or fluorogenic 
substrates are commonly used for protease assay.35 
 
1.4. Colorimetric method 
 
Chromogenic substrates for protease assay are comprised of a substrate peptide and a dye, 
and its absorbance at particular wavelength is changed before and after enzymatic 
degradation. In detection of protease activity, Peptide-p-nitroanilide (pNA) is commonly 
used as the chromogenic substrate.26 When colorless Peptide-pNA is cleaved by protease, 
yellow p-nitroaniline is liberated (Fig. 3). Hence, protease activity can be detected by 
measurement of the absorbance of free p-nitroaniline at 405 nm. 
 
 
Fig. 3  Schematic representation of the detection of protease activity using Peptide-
pNA. 
 
A number of protease activities such as trypsin, subtilisin, and chymotrypsin could be 
successfully detected using specific Peptide-pNA.37−39 However, in protease assay, 
fluorometric method is preferable to colorimetric method in terms of its sensitivity. 
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1.5. Fluorometric method 
 
Fluorogenic substrates have been more eagerly developed as the sensitivity of 
fluorometric method is generally three orders of magnitude higher than colorimetric 
method.40,41 Fluorogenic substrates change its fluorescent property after hydrolyzation by 
a specific protease. Measurement of the degree of this alteration allows for the detection 
of the activity of target protease. Until now, a variety of fluorogenic substrates for 
protease assay have been developed. 
 
1.5.1. Peptide-MCA 
 
Peptide-4-methylcoumarin amide (MCA) is one of commonly used fluorogenic substrates 
for protease assay. Zimmerman et al. was the first to report that Peptide-MCA was 
successfully applied to the detection of protease activity as a substrate in 1976.42 Since 
then, Peptide-MCA was applied to the detection of many proteases.43−48 Peptide-MCA 
emits the fluorescence at 400 nm upon excitation at 330 nm. 7-Amino-4-methylcoumarin 
(AMC) is released when Peptide-MCA is hydrolyzed by protease (Fig. 4). AMC emits 
the fluorescence at 460 nm upon excitation at 380 nm. Therefore, measuring the degree 
of the change in fluorescence intensity at 460 nm allows for the detection of protease 
activity. The fluorescence of AMC can be measured upon the light which is selectively 
excited not MCA group but AMC, resulting the detection with high signal-to-noise (S/N) 
ratio. 
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Fig. 4  Schematic representation of the detection of protease activity using Peptide-
MCA. 
 
However, in the case of an AMC-based assay, the specificity for the P1′ amino acid 
residue (counterpart of the S1′ subsite of the protease), which is important for substrate 
recognition and catalytic efficiency, is not reflected in the artificial substrate (Fig. 5).49 
 
 
Fig. 5  The subsites of proteases. 
 
Additionally, AMC-based assay requires ultraviolet (UV) light irradiation for the 
excitation of AMC, which may cause unexpected autofluorescence and photodamage to 
some biological species.50 
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1.5.2. Rhodamine substrate 
 
Rhodamine-based substrate for protease assay was reported by Leytus et al. in 1983.51 
Rhodamine dyes are fluorophores which belong to the family of xanthenes along with 
fluorescein and eosin dyes. Rhodamines are used for fluorogenic substrates owing to their 
excellent photostability and photophysical properties such as high quantum yield, and a 
variety of derivatives of rhodamine have been developed (Table 1). For protease assay, 
rhodamine 110 is the most used.52 
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Table 1  Commercially available rhodamines.53 
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Double-substitution of rhodamine 110 yields a non-fluorescent lactone, and the 
hydrolyzation of the substrate at two cleavage sites by protease is ascribed to the 
fluorescence emission of rhodamine 110 (Fig. 6). 
 
 
Fig. 6  Fluorescent reporter system for measuring the activity of α-chymotrypsin at the 
single-molecule level.54 
 
Although rhodamine 110-based substrates have been adopted as fluorogenic substrates 
for many proteases,55−59 these two step enzymatic reactions cause not only a reduction in 
the speed and efficiency of fluorescence activation but also complicated kinetic 
analysis.60 In addition, as with Peptide-MCA, the specificity of the P′ site is not reflected 
in the synthesized substrate. 
 
1.5.3. FRET-based substrate 
 
Intramolecularly quenched fluorescent substrates (IQFS), one of Förster resonance 
energy transfer (FRET)-based substrates, have been used for the detection of various 
protease activities.61−67 FRET is that the transfer of fluorescence energy from a donor dye 
to an acceptor dye whenever the distance between both dyes is smaller than a critical 
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radius known as the Förster radius (typically 3–6 nm).68,69 Latt. et al. was the first to 
report that FRET-based fluorescent substrate for protease assay was successfully 
developed in 1972.70 Proximate fluorophore and quencher in the substrate occur FRET, 
and fluorescence of the substrate is quenched (Fig. 7). Degradation of the substrate 
peptide by protease leads to the separation of the intramolecular fluorophore-quencher 
pair, allowing the increase of the fluorescence of the fluorophore. 
 
 
Fig. 7  Schematic representation of the detection of protease activity using IQFS. 
 
Recently, quantum dots (QDs) have been reported as attractable inorganic fluorophores 
in FRET technologies for protease assay.71−73 Luminescent semiconductor QDs have 
unique optical properties for bioanalytical applications. QDs have broad absorption and 
narrow emission spectra, which enable the excitation by a wide range of wavelength and 
multi-color sensing.74 In addition, the emission profile can be precisely controlled through 
the variation of core size, composition, and surface coatings (Fig. 8).75 
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Fig. 8  Narrow size-tunable light emission profile enables precise control over the 
probe color via varying the nanoparticle size.76 
 
In protease assay, QD-peptide conjugate, which has substrate peptide for target protease 
with fluorophore or quencher, has been used. The fluorescence of the QD-peptide 
conjugate is quenched by FRET (Fig. 9). The substrate peptide is specifically cleaved by 
protease, followed by the release of the acceptor fluorophore from the QD-peptide 
conjugate, leading to the recovery of QD fluorescence.77 
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Fig. 9  QD-FRET sensor for the study of protease.78 
 
However, in a FRET-based assay, the combination of fluorophores and quenchers can be 
limiting, and expensive fluorophores or quenchers are often required. Furthermore, the 
synthesis of FRET-based substrate is usually complicated because at least one pair of 
orthogonal protecting groups is needed so that the two different dyes required for the 
FRET are coupled. 
 
1.7. Aim of this study 
 
Proteases are significant physiological enzymes, and a variety of methodologies have 
been keenly studied. Especially, the fluorescent peptide probe is considered as a strong 
tool for biochemical research and clinical diagnostic application because fluorometric 
method using the fluorogenic peptide substrate enables facile and sensitive detection of 
protease activity and evaluation of protease inhibitor. Although currently Peptide-MCA 
and FRET-based substrates for many kinds of proteases are commercially available, 
meaning these fluorogenic peptide substrates are considered as standard fluorescent 
peptide probes for protease assay, these substrates are not necessarily versatile. In the case 
of Peptide-MCA, MCA group next to the proteolytic cleavage site prohibits the reflection 
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and characterization of prime subsites in the substrate peptide. As for FRET-based 
substrate, relatively complicated synthesis is inevitable due to the incorporation of two 
different dyes. In addition, the limitation of the combination of fluorophore and quencher 
may demand the use of expensive dyes. 
 
To overcome above defects, in this study, we developed novel doubly labelled fluorescent 
peptide probes for protease assays exploiting the intramolecular interaction between 
identical fluorophores such as internal self-quenching or excimer formation. 
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Chapter 2 
 
Novel self-quenching-based substrates for measurement of thrombin, 
trypsin, and chymotrypsin activities 
 
2.1. Introduction 
 
As mentioned in preceding chapter, commercially available fluorescent peptide probes 
such as Peptide-MCA and FRET-based substrate have some problems which are the 
deficient reflection of the specificity in prime region, complicated synthesis, and the 
restriction attributed to fluorophore and quencher. To solve these challenging matters, we 
focused on self-quenching-based substrates. 
 
Several self-quenching-based substrates, which are peptide substrates multiply labelled 
with the identical fluorophores, have been already reported. The fluorescence of these 
substrates is self-quenched owing to the highly assembled fluorophores on the substrates. 
The release of these concentrated fluorophores by a protease allows for fluorescence 
recovery. Packard et al. reported the design of profluorescent elastase substrates where 
an undecapeptide in the substrate is labelled with two xanthene dyes on each side of the 
cleavage site.1 While these substrates showed high quenching efficiency, the synthesis of 
these substrates remain unsophisticated. The synthesis of the substrates requires the 
coupling of two tetramethylrhodamines to the substrate in liquid phase synthesis after the 
completion of the synthesis of the substrate peptide by solid-phase peptide synthesis 
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(SPPS) because their substrates do not have branched unit. Ternon et al., Galande et al., 
and Avlonitis et al. designed multi-branched fluorescent probes, which consisted of 
branched unit such as lysines or a 1,1,1-tris(hydroxymethyl)aminomethane derivative, 
substrate peptides, and several identical fluorophores.2−4 However, in the case of these 
substrates, three or more fluorophores should be coupled to multi-branched compound on 
the resin, meaning this is directed against simple synthesis. In addition, these multi-
labelled substrates tend to be poor solubility and sterically hindered, and have several 
proteolytic cleavage sites. These properties cause slow hydrolyzation and complication 
of the reaction system. 
 
There is still room for improvement in design of self-quenching-based substrates for 
easier synthesis and kinetic analysis. Moreover, detailed kinetic assays and inhibitor 
evaluation using these substrates have not been described yet.  
 
2.2. Design 
 
In this study, we designed two simple and easily synthesizable self-quenching-based 
substrates 1 and 2 for the detection of thrombin and trypsin activities (Fig. 1). A kinetic 
assay and inhibitor evaluation were carried out using these substrates. Additionally, 
substrate 3 was designed for chymotrypsin (Fig. 2). 
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Fig. 1  Design of the self-quenching-based substrates for trypsin. 
 
 
Fig. 2  Design of the self-quenching-based substrate for chymotrypsin. 
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The self-quenching-based substrates consist of two fluorescein isothiocyanates (FITCs) 
and the corresponding enzyme specific peptides. FITC has an excellent fluorescence 
quantum yield, good water solubility, and it readily reacts with amino groups. Therefore, 
it is commonly applied in a variety of assays. One extra amino acid was inserted between 
the arginine and lysine residues in 2 to demonstrate that the specificity of the P1′ amino 
acid residue can be reflected in the artificial substrate. These two FITC-binding substrate 
peptides are linked to two amino groups of lysine. Lysine was selected for the branched 
unit because of the convenient preparation of these substrates using only SPPS. Two 
FITCs were densely assembled on the substrates to quench the fluorescence via self-
quenching. Before the proteolytic cleavage, the emission of FITC is quenched by 
intramolecular self-quenching (Fig. 3). After the cleavage, FITC is liberated, and its 
fluorescence is recovered. 
 
 
Fig. 3  Schematic representation of the detection system for 2. 
 
The syntheses of these substrates were very simple (Scheme 1 and 2). The corresponding 
FITC-peptide chains of the substrate peptides were elongated from the two amino groups 
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of lysine on the amide resin using standard Fmoc SPPS. After cleavage from the solid 
support, three self-quenching-based substrates 1, 2, and 3 were obtained. 
 
 
 
Scheme 1  Synthetic routes of 1 and 2. 
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Scheme 2  Synthetic route of 3. 
 
2.3. Target proteases 
 
2.3.1. Thrombin 
 
Thrombin (EC 3.4.21.5) is a trypsin-like serine protease in blood, and can cleave 
polypeptide substrates at Arg/Lys-Xaa bonds (where Xaa is any amino acid). Thrombin 
serves as a regulator in the cascade of blood coagulation (Fig. 4).5 
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Fig. 4  Multifunctional roles of thrombin.6 
 
Thrombin is originally secreted as its inactive precursor prothrombin from liver. Cleavage 
of prothrombin at R323 by factor Xa which is one of serine proteases results in the 
conversion of prothrombin into meizothrombin as an intermediate, followed by 
subsequent hydrolyzation at R274 to produce thrombin (Fig. 5). When these bond 
cleavages proceed in the opposite order (cleavage at R323, followed by cleavage at R274), 
prethrombin is yielded as an intermediate.7,8  
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Fig. 5  Pathways of prothrombin activation.9 
 
Thrombin cleaves fibrinogen to form fibrin which is the scaffolding of thrombosis.10,11 In 
addition, thrombin plays key roles in platelet receptor activation, endothelium activation, 
and activation of factors V, VIII, XI (coagulation factors), and XIII (fibrin stabilizing 
factor) (Fig. 6).12−14  
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Fig. 6  Antagonizing actions of thrombin in coagulation cascade.15 
 
Therefore, thrombin may be associated with various diseases such as thrombosis, 
inflammation, Alzheimer’s disease, and cancers.16−19 Recently, it was reported that 
urinary thrombin activity could be used as a specific biomarker for crescentic 
glomerulonephritis (CresGN).20,21 CresGN rapidly progresses to renal failure; however, 
the appropriate treatment at early stages may cure of this disease without impaired renal 
function. Hence, the detection of urinary thrombin activity is required for the noninvasive 
diagnosis of CresGN at early stages. 
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2.3.2. Trypsin 
 
Trypsin (EC 3.4.21.4) can also cleave polypeptide substrates at Arg/Lys-Xaa bonds and 
is required for protein digestion.22,23 Trypsin is primarily produced as its inactive 
precursor trypsinogen from pancreas, and trypsinogen is activated as trypsin by 
enterokinase (Fig. 7).24,25 Moreover, trypsin can activate not only trypsinogen and many 
other digestive proenzymes (e.g. chymotrypsinogen, proelastase, kallikreinogen, 
procarboxypeptidase, and some prolipases) but also pancreatic and inflammatory cells. 
 
 
Fig. 7  Activation of trypsin, chymotrypsin, and other digestive proenzymes. 
 
Therefore, trypsin plays an essential role in regulating pancreatic exocrine function. 
However, overexpression or deficiency of trypsin is directly associated with some types 
of pancreatic and other diseases.26−30 Although trypsin is commonly used as a model 
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protease because it is inexpensive and readily available, trypsin can be considered as a 
promising biomarker for some pancreatic diseases. 
 
2.3.3. Chymotrypsin 
 
Chymotrypsin (EC 3.4.21.1) is also one of the most common serine proteases, and is 
relevant to many physiological processes such as digestion, hemostasis, apoptosis, signal 
transduction, reproduction, and the immune response.4 Chymotrypsin is specifically 
hydrolyzed the peptide bond at Phe/Tyr/Trp-Xaa of polypeptide. Chymotrypsin is 
initially secreted as its inactive precursor chymotrypsinogen from pancreas, and 
chymotrypsinogen is activated as chymotrypsin by trypsin (Fig. 7).26 Chymotrypsin is 
known as not only a model protease as well trypsin but also one of disease-related 
proteases. Chymotrypsin is associated with pancreatic fibrosis, maldigestion, diabetes 
mellitus, hypertension, inflammation, and many types of cancers, particularly pancreatic 
cancer.31 Furthermore, elevated level of chymotrypsin in serum is involved in acute 
pancreatitis and renal failure.32 Therefore, the detection of chymotrypsin activity is 
significant in drug discovery and clinical diagnosis. 
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2.4. Experimental section 
 
2.4.1. Materials and instruments 
 
All Fmoc-protected amino acids, Fmoc-NH-SAL resin, piperidine, O-(1H-benzotriazol-
1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), 1-hydroxy-1H-
benzotriazole hydrate (HOBt·H2O), N,N-diisopropylethylamine (DIEA), and 2,2,2-
trifluoroacetic acid (TFA) were purchased from Watanabe Chemical Industries, Ltd. 
FITC-I was supplied from Dojindo Molecular Technologies, Inc. α-Trypsin from bovine 
pancreas, α-chymotrypsin from bovine pancreas, thrombin from human plasma, and 
Bowman-Birk inhibitor from Glycine max (soybean) were obtained from Sigma-Aldrich 
Co. LLC. All solvents and other reagents were ordered from Wako Pure Chemical 
Industries, Ltd. The assay buffer solution was 50 mM Tris-HCl buffer (pH 8.0) containing 
150 mM NaCl, 1 mM CaCl2, and 0.1 mg/mL bovine serum albumin (BSA). Analytical 
high performance liquid chromatography (HPLC) was performed on a Hitachi L-7100 
instrument equipped with a chromolith performance RP-18e column (4.6 x 100 mm; 
Merck). The mobile phases were 0.1% TFA in H2O (solvent A) and 0.1% TFA in H2O 
(solvent B) using a linear gradient of solvent B in solvent A (0–50% over 15 min) with a 
flow rate of 2.0 mL/min, and absorbance at 220 nm was used for the detection. Semi-
preparative HPLC was performed on a Hitachi L-7100 instrument equipped with an 
XTerra Prep MS C18 OBD 10 µm (19 x 150 mm; Waters). The mobile phases were 0.1% 
TFA in H2O (solvent A) and 0.1% TFA in H2O (solvent B) using a linear gradient of 
solvent B in solvent A (25–35% or 40–50% over 30 min) with a flow rate of 5.0 mL/min, 
and absorbance at 220 nm or 290 nm was used for the detection. High resolution mass 
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spectrometry (HR-MS) (Electrospray ionization time-of-flight mass spectrometer (ESI-
TOF-MS)) data were measured on a JEOL THE ACCUTOF LC-PLUS JMS-T100LP 
instrument. pH measurements were made with a D-71 LAQUA portable pH meter 
(Horiba). Lyophilization was carried out on a VD-800F freeze dryer (TAITEC). 
Absorbance was measured using a GE Healthcare Ultrospec 3300 pro UV/Vis 
spectrometer or a JASCO V-550 UV/VIS spectrophotometer. Fluorescence spectra were 
measured on a JASCO FP-6600 spectrofluorometer. The enzyme reaction was 
investigated using a Wallac ARVO SX 1420 Multilabel Counter on a 96-well black plate. 
Deionized water was obtained from a Milli-Q Plus system (Millipore). 
 
2.4.2. Synthesis 
 
2.4.2.1. Solid-phase synthesis of 1, 2, and 3 
 
Fmoc-L-Lys(Fmoc)-OH was loaded onto Fmoc-NH-SAL resin (0.54 mmol/g resin) using 
Fmoc/piperidine strategies on a 0.432 mmol scale. HBTU and HOBt·H2O were used as 
activating agents. After capping the N-terminal with acetic anhydride, the corresponding 
peptide chain was elongated. Subsequently, FITC-I was coupled to the elongated peptide 
in the presence of DIEA. The resin-supported peptide was cleaved from the resin in the 
cleavage cocktail (TFA/Triisopropylsilane/H2O = 95:2.5:2.5). The peptide was 
precipitated by ether in an ice bath. The crude peptide was purified by HPLC. The purified 
substrate was analyzed by HR-MS (ESI-TOF-MS). 
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Substrate 1; Overall yield: 17% (0.012 g, 0.006 mmol). m/z calcd. for [(M+H)+] 
C86H104N19O19S2: 1770.71972; found: 1770.72794, Retention time: 8.51 min.  
 
 
Fig. 8  HPLC profile of 1. HPLC conditions: a linear gradient of solvent B in solvent 
A (0–50% over 15 min); Chromolith performance RP-18e column (4.6 x 100 mm; 
Merck); flow rate, 2 mL/min; solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in 
CH3CN; detection at 220 nm. 
 
 
Fig. 9  MASS spectrum of 1. 
 
Substrate 2; Overall yield: 24% (0.022 g, 0.010 mmol). m/z calcd. for [(M+H)+] 
C90H110N21O21S2: 1884.76265; found: 1884.76489, Retention time: 7.86 min.  
 
8.51 min 
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Fig. 10  HPLC profile of 2. HPLC conditions: a linear gradient of solvent B in solvent 
A (0–50% over 15 min); Chromolith performance RP-18e column (4.6 x 100 mm; 
Merck); flow rate, 2 mL/min; solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in 
CH3CN; detection at 220 nm. 
 
 
Fig. 11  MASS spectrum of 2. 
 
Substrate 3; Overall yield: 7% (0.011 g, 0.007 mmol). m/z calcd. for [(M+H)+] 
C84H86N13O19S2: 1644.56043; found: 1644.55988, Retention time: 8.42 min. 
 
 
Fig. 12  HPLC profile of 3. HPLC conditions: a linear gradient of solvent B in solvent 
A (0–50% over 15 min); Chromolith performance RP-18e column (4.6 x 100 mm; 
Merck); flow rate, 2 mL/min; solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in 
CH3CN; detection at 220 nm. 
 
7.86 min 
8.42 min 
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Fig. 13  MASS spectrum of 3. 
 
2.4.2.2. Solid-phase synthesis of 4 and 5 
 
 
Fig. 14  Cleavable substrate residues 4 and 5. 
 
Fmoc-L-Lys(Boc)-OH or Boc-L-Lys(Fmoc)-OH was loaded onto Fmoc-NH-SAL resin 
(0.56 mmol/g resin) using Fmoc/piperidine strategies on a 0.448 mmol scale. HBTU and 
HOBt·H2O were used as activating agents. After capping the N-terminal with acetic 
anhydride, the corresponding peptide chain was elongated. Subsequently, FITC-I was 
coupled to the elongated peptide in the presence of DIEA. The resin-supported peptide 
was cleaved from the resin in the cleavage cocktail (TFA/Triisopropylsilane/H2O = 
95:2.5:2.5). The peptide was precipitated by ether in an ice bath. The crude peptide was 
purified by HPLC. The purified substrate was analyzed by HR-MS (ESI-TOF-MS).  
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Substrate 4; Overall yield: 24% (0.040 g, 0.034 mmol). m/z calcd. for [(M+H)+] 
C46H60N11O10S: 958.42453; found: 958.42301, Retention time: 5.32 min.  
 
 
Fig. 15  HPLC profile of 4. HPLC conditions: a linear gradient of solvent B in solvent 
A (0–50% over 15 min); Chromolith performance RP-18e column (4.6 x 100 mm; 
Merck); flow rate, 2 mL/min; solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in 
CH3CN; detection at 220 nm. 
 
 
Fig. 16  MASS spectrum of 4. 
 
Substrate 5; Overall yield: 24% (0.043 g, 0.036 mmol). m/z calcd. for [(M+H)+] 
C46H60N11O10S: 958.42453; found: 958.42737, Retention time: 5.30 min. 
 
 
5.32 min 
47 
 
 
Fig. 17  HPLC profile of 5. HPLC conditions: a linear gradient of solvent B in solvent 
A (0–50% over 15 min); Chromolith performance RP-18e column (4.6 x 100 mm; 
Merck); flow rate, 2 mL/min; solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in 
CH3CN; detection at 220 nm. 
 
 
Fig. 18  MASS spectrum of 5. 
 
2.4.3. Analysis 
 
2.4.3.1. Preparation of stock solutions 
 
The stock solutions of 1, 2, 3, 4, 5, iBoc-VPR-MCA (6), and FITC-β-Ala-OH were 
prepared in dimethylsulfoxide (DMSO) and stored in a refrigerator. The concentration of 
the FITC solutions was determined by the molar extinction coefficient of FITC-β-Ala-
OH at 495 nm (ε495 = 76,300 M-1·cm-1). The stock solution of trypsin, chymotrypsin, and 
thrombin in the micromolar range was prepared in the buffer and stored in a freezer. The 
concentration of the trypsin solution was determined using the molar extinction 
coefficient of trypsin at 280 nm (ε280 = 36,280 M-1·cm-1).33 The concentration of the 
5.30 min 
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chymotrypsin solution was determined using the molar extinction coefficient of 
chymotrypsin at 280 nm (ε280 = 50,000 M-1·cm-1).34 The concentration of the thrombin 
solution was determined using the molar extinction coefficient of thrombin at 280 nm 
(ε280 = 66,800 M-1 cm-1).35 The stock solution of Bowman–Birk inhibitor (BBI) in the 
micromolar range was prepared in distilled water and stored in a freezer. The 
concentration of BBI was estimated spectrophotometrically using the values of Mr = 
7,975 Da and A1%280 = 4.4.36 The stock solutions were diluted with the buffer prior to the 
fluorescence measurements. The concentration of DMSO in the assay was less than 5%. 
 
2.4.3.2. Investigation of self-quenching efficiency of 1, 2, and 3 
 
The stock solutions of 1, 2, 3, and FITC-β-Ala-OH were diluted with the buffer, and an 
equimolar solution of each of the FITC moieties (1 µM) was prepared. The fluorescence 
spectra of these solutions upon excitation at 485 nm were measured with a 
spectrofluorometer. The self-quenching efficiency was calculated by using the following 
equation: 
Self-Quenching efficiency (%)= (1 −
𝐹substrate
𝐹control
) × 100 (1) 
where Fsubstrate is the fluorescence intensity of 1, 2, or 3 and Fcontrol is the fluorescence 
intensity of FITC-β-Ala-OH. 
 
 
49 
 
2.4.3.3. Examination of influence of 4 and 5 on trypsin assays using 1 
 
The stock solutions of 1, 4, and 5 were diluted with the buffer, and the final concentration 
of 1 was adjusted to 10 µM. The final concentration of 4 or 5 ranged from 2 µM to 10 
µM. The stock solution of trypsin was also diluted with the buffer, and the final 
concentration of trypsin was adjusted to 1 nM. The hydrolysis of 1 mixed with the 
different concentrations of 4 or 5 was initiated by the addition of trypsin solution, and 
monitored fluorometrically by using a microplate reader with an excitation of 485 nm and 
an emission of 535 nm. According to these fluorescence recovery, the initial velocities 
were calculated and compared respectively. 
 
2.4.3.4. Calculation of kinetic parameters of 1, 2, 3, and 6 
 
The stock solutions of 1, 2, 3, and 6 were diluted with the buffer, and the final 
concentration of these substrates ranged from 1 to 32 µM. The stock solution of trypsin 
was also diluted with the buffer, and the final concentration of trypsin was adjusted to 1 
nM. Similarly, the stock solution of chymotrypsin was also diluted with the buffer, and 
the final concentration of chymotrypsin was adjusted to 10 nM. The stock solution of 
thrombin was also diluted with the buffer, and the final concentration of thrombin was 
adjusted to 296 nM (for 1), 196 nM (for 2), and 1 nM (for 3). The hydrolysis of the 
different concentrations of 1, 2, and 3 was initiated by the addition of trypsin, 
chymotrypsin, or thrombin solution, and monitored fluorometrically by using a 
microplate reader with an excitation of 485 nm and an emission of 535 nm. For 6, an 
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excitation of 370 nm and emission of 460 nm were adopted. The kinetic parameters of 
Km, Vmax, kcat, and kcat/Km were calculated by fitting the Michaelis–Menten equation 
described below with the least-squares method. 
𝑣0 =
𝑉max[S]
𝐾m + [S]
 (2) 
𝑘cat =
𝑉max
[E]
 (3) 
where v0 is the initial velocity, [S] is the substrate concentration, Km is the Michaelis 
constant, Vmax is the maximal velocity, [E] is the protease concentration, and kcat is the 
turnover number. 
 
2.4.3.5. Determination of detection limit in trypsin and chymotrypsin 
assays 
 
The final concentration of 1, 2, and 3 was adjusted to 10 µM. The final concentration of 
trypsin ranged from 10 pM to 1 nM, and the final concentration of chymotrypsin ranged 
from 250 pM to 10 nM. The fluorescence recovery of each substrate in the presence of 
different concentrations of trypsin or chymotrypsin was measured using a microplate 
reader. The detection limit for trypsin or chymotrypsin was calculated using the following 
formula:37 
Limit of detection (LOD) =
3𝑠𝑦/𝑥
𝐾
 (4) 
where sy/x is the standard deviation of y-residuals and K is the slope of the linear plot of 
fluorescence intensity versus trypsin or chymotrypsin concentration. 
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2.4.3.6. Determination of IC50 and Ki of BBI 
 
The final concentration of 1 and 2 was adjusted to 10 µM, and the final concentration of 
trypsin was adjusted to 1 nM. The final concentration of BBI ranged from 0 to 40 nM. 
Hydrolysis reactions for the different concentrations of BBI were initiated by the addition 
of the trypsin solution, and monitored fluorometrically by using a microplate reader as 
mentioned above. The IC50 for BBI was estimated by fitting the Hill equation described 
below with the least-squares method.38 
Inhibition efficiency (%) = 𝐸bottom +
𝐸top − 𝐸bottom
1 + exp{𝑛(ln IC50 − ln[I])}
 (5) 
where Ebottom is the minimal inhibition efficiency (0%), Etop is the maximal inhibition 
efficiency (100%), n is the Hill constant, and [I] is the BBI concentration. 
 
Subsequently, the Ki for BBI was estimated by fitting the Morrison equation described 
below with the least-squares method.39 
𝑣i
𝑣0
= 1 −
([E] + [I] + 𝐾i) − √([E] + [I] + 𝐾i)2 − 4[E][I]
2[E]
 (6) 
where vi is the initial velocity in the presence of BBI, v0 is the initial velocity in the 
absence of BBI, [E] is the trypsin concentration, [I] is the BBI concentration, and Ki is 
the dissociation constant. 
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2.5. Results and discussion 
 
2.5.1. Investigation of self-quenching efficiency 
 
Initially, we investigated the self-quenching efficiency of 1, 2, and 3. A total of 0.5 µM 
of 1, 2, and 3 were prepared in 50 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl, 
1 mM CaCl2, and 0.1 mg/mL BSA. Similarly, 1 µM of a FITC-β-Ala-OH solution was 
also prepared in the buffer as a control sample. All of the solutions contained 1 µM of the 
FITC moieties, a concentration that did not cause self-quenching in a preliminary 
experiment. The fluorescence spectra upon excitation at 485 nm of each sample prior to 
the addition of trypsin or chymotrypsin were measured using a spectrofluorometer (Fig. 
19). Substrates 1, 2, and 3 exhibited lower fluorescence emission compared with FITC-
β-Ala-OH. Hence, it was demonstrated that 1, 2, and 3 showed quenched fluorescence by 
self-quenching. Using the spectral data, the quenching efficiencies were calculated. The 
substrates displayed moderate quenching efficiency with 60.7% for 1, 64.1% for 2, and 
63.8% for 3.  
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Fig. 19  Fluorescent spectra of 1, 2, 3 (0.5 µM), and FITC-β-Ala-OH (1 µM) in 50 mM 
Tris-HCl buffer (pH 8.0) containing 150 mM NaCl, 1 mM CaCl2, and 0.1 mg/mL BSA 
at room temperature. Excitation wavelength was 485 nm. 
 
2.5.2. Effect of cleavable substrate residues on kinetic assays 
 
The substrates had two protease cleavage sites per molecule. For example, 1 contains two 
cleavage sites for trypsin. Cleaved substrates 4 and 5 still contain one cleavage site for 
trypsin (Scheme 3). Therefore, 4 and 5 might function as inhibitors. However, since the 
substrates were characterized by measuring the initial rates of turnover, any inhibition 
resulting from the production of 4 and 5 was minimized. As a control, to confirm that the 
products 4 and 5 did not significantly inhibit the turnover of their respective substrates, 
the initial velocity was calculated using 10 µM of 1 combined with 10% (based on the 
concentration of 1) of 4 or 5 in the presence of 1 nM of trypsin. Under these conditions, 
the initial velocity decreased by only 3.2–3.5% compared with the rate of turnover of 
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substrate alone. It is likely that 4 and 5 are poor inhibitors for trypsin because of their 
increased hydrophilicity compared to the corresponding substrate caused by the release 
of one of the two hydrophobic fluorescent peptides, and thus, trypsin has reduced affinity 
for 4 and 5. According to the above-mentioned results, analysis was carried out using 
standard Michaelis–Menten kinetic treatment. 
 
 
Scheme 3  Generation of hydrolysable residues 4 and 5. 
 
2.5.3. Kinetic assays of trypsin and chymotrypsin 
 
Next, the increase in the fluorescence intensity of different concentrations of the 
substrates during tryptic or chymotryptic degradation was monitored. To each 
concentration of the substrates (1, 2, 4, 10, 16, 24, and 32 µM), 1 nM of trypsin or 10 nM 
of chymotrypsin was added, and the fluorescence recovery at 535 nm upon excitation at 
485 nm was recorded using a fluorescence plate reader. Subsequently, the kinetic 
parameters for trypsin were calculated. According to the fluorescence recovery, the 
increases in the fluorescence intensities were converted to the corresponding initial 
velocities for the hydrolysis reactions. The kinetic parameters for trypsin or chymotrypsin 
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activity such as Km, Vmax, kcat, and kcat/Km were estimated by fitting the data to the 
Michaelis–Menten equation using the least-squares method (Fig. 20).  
 
 
Fig. 20  Michaelis–Menten curve of 1 and 2 catalyzed by trypsin (1 nM) in 50 mM 
Tris-HCl buffer (pH 8.0) containing 150 mM NaCl, 1 mM CaCl2, and 0.1 mg/mL BSA 
at room temperature with fluorometric method. Excitation/emission wavelengths were 
485 nm/535 nm. 
 
The Km value of 2 was 1.5-fold higher than that of 1, which meant that the affinity of 2 
toward trypsin was slightly less than that of 1 (Table 1). The retention time of 2 from H 
analysis was shorter than that of 1, indicating that the hydrophobicity of 2 was lower than 
that of 1. As a result of the difference of the hydrophobic properties between 1 and 2, it 
was expected that a difference of Km values might be observed. The Vmax and kcat values 
of 2 were 1.5-fold higher than that of 1, which indicated that 2 was easily liberated from 
trypsin because the extra glycine offered conformational and hydrophilic benefits for the 
release of the enzyme from the enzyme-substrate complex. The resulting kcat/Km values 
of 1 and 2 were almost equal. This indicated that extra glycine in 2 only minimally 
affected the interaction of 1 and 2 with trypsin.  
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Furthermore, kinetic analysis of iBoc-VPR-MCA (6), which is a commonly used 
fluorescent substrate, was determined for comparison purposes (Fig. 21). 
 
 
Fig. 21  Standard fluorescent probe, iBoc-VPR-MCA (6). 
 
After addition of trypsin into the substrate solutions, fluorescence recovery at 460 nm 
upon excitation at 370 nm was recorded using a fluorescence plate reader, and initial 
velocity was calculated (Fig. 22).  
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Fig. 22  Michaelis–Menten curve of 6 catalyzed by trypsin (1 nM) in 50 mM Tris-HCl 
buffer (pH 8.0) containing 150 mM NaCl, 1 mM CaCl2, and 0.1 mg/mL BSA at room 
temperature with fluorometric method. Excitation/emission wavelengths were 370 
nm/460 nm. 
 
While the Km value of 6 was lower than that of 1 and 2, the Vmax and kcat values of 6 were 
lower than those of 2 (Table 1). These data indicated that the turnover number for 2 was 
larger than that for 6 although the affinity of trypsin toward 6 was stronger than its affinity 
toward 1 or 2. The resulting kcat/Km values revealed that the activities of trypsin for 1 and 
2 were almost comparable to the standard fluorescent substrate 6. 
 
Similarly, the kinetic parameters for chymotrypsin were also estimated by fitting the data 
to the Michaelis–Menten equation using 3 as a substrate (Fig. 23).  
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Fig. 23  Michaelis–Menten curve of 3 catalyzed by chymotrypsin (10 nM) in 50 mM 
Tris-HCl buffer (pH 8.0) containing 150 mM NaCl, 1 mM CaCl2, and 0.1 mg/mL BSA 
at room temperature with fluorometric method. Excitation/emission wavelengths were 
485 nm/535 nm. 
 
The Km, Vmax, and kcat values of 3 were 15.5 µM, 9.46 nM·s-1, and 0.946 s-1 respectively, 
and the resulting kcat/Km was 6.1 x 10-2 µM-1·s-1 (Table 1). This indicated that self-
quenching-based substrates were applicable for not only trypsin but also chymotrypsin.  
 
Table 1  Summary of the kinetic parameters of 1, 2, 3, and 6 for trypsin or 
chymotrypsin. 
Substrate Km (μM) Vmax (nM·s-1) kcat (s-1) kcat/Km (μM-1·s-1) 
1 6.31 8.91 8.91 1.41 
2 9.48 13.0 13.0 1.37 
6 2.80 8.04 8.04 2.87 
3 15.5 9.46 0.946 6.1 x 10-2 
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2.5.4. Determination of detection limit of trypsin and chymotrypsin 
 
To achieve a quantitative assay for trypsin using our substrates, the detection limit was 
examined. The concentration of the substrates was fixed at 10 µM, and different 
concentrations of trypsin (0.001 (only tested on 6), 0.05, 0.1, 0.25, 0.5, 0.75, and 1 nM) 
were employed. According to the linear relationship observed between the relative 
fluorescence recovery and trypsin concentration, the detection limits for the assays were 
calculated (Fig. 24). A lower limit of 111 pM trypsin could catalyze the fluorescence 
recovery of substrates 1 and 2 compared with 30.9 pM trypsin for 6. A lower limit of 711 
pM chymotrypsin for the catalysis of 3 was also obtained. 
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Fig. 24  The linear relationship between amounts of change of the fluorescence 
intensity of the substrates (10 µM) within a set time of 20 minutes. Excitation/emission 
wavelengths were 485 nm/535 nm for 1–3 and 370 nm/460 nm for 6. 
 
2.5.5. Evaluation of trypsin inhibitor 
 
Next, we confirmed whether our substrates could be used for inhibitor evaluation. The 
inhibition of trypsin activity by the Bowman–Birk inhibitor (BBI), which is the most 
commonly used trypsin inhibitor, was investigated using our substrates. To 10 µM of 1, 
2, and 6, different concentrations of BBI (0, 2, 5, 10, 15, 20, 30, and 40 nM) were added, 
followed by addition of 1 nM of trypsin. During tryptic cleavage, fluorescence recovery 
at 535 nm upon excitation at 485 nm (for 1 and 2) or 460 nm with excitation at 370 nm 
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(for 6) was recorded by a fluorescence plate reader. As expected, the higher the 
concentration of BBI present in the reaction mixture, the slower the fluorescence recovery 
was (Fig. 25).  
 
 
Fig. 25  Plots of inhibition efficiencies of BBI toward trypsin (1 nM) with the 
substrates (10 µM). 
 
After plotting the inhibition efficiencies versus the BBI concentrations, the IC50 values 
were calculated by fitting the data to the Hill equation (Fig. 26). The IC50 values for BBI 
using 1, 2, and 6 as substrates were estimated as 6.64, 6.34, and 26.3 nM respectively.  
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Fig. 26  Semilogarithmic plots and fitting curve with Hill equation of inhibition 
efficiencies of BBI toward trypsin (1 nM) with 10 µM of 1 (a), 2 (b), and 6 (c). 
 
Because IC50 values depend on enzyme concentration,40 the Ki values for BBI were 
calculated by using the Morrison equation to get a more accurate representation of the 
inhibition (Fig. 27). The Ki values determined from the Morrison equation were 5.96 nM 
(1), 5.59 nM (2), and 26.1 nM (6). The Ki of BBI has been reported to be between 10-7 
and 10-9 M, and our values fall within this range.41 Therefore, these self-quenching-based 
substrates can be used for evaluation of inhibitors of trypsin. 
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Fig. 27  Plots and fitting curve with Morrison equation of inhibition efficiencies of 
BBI toward trypsin (1 nM) with 10 µM of 1 (a), 2 (b), and 6 (c). 
 
2.5.6. Kinetic assay of thrombin 
 
Finally, the increase in the fluorescence intensity of different concentrations of the 
substrates during thrombin cleavage was monitored. To each concentration of the 
substrates (0.893, 1.79, 3.58, 8.94, 14.3, 21.5, and 28.6 µM for 1, 0.945, 1.90, 3.79, 9.47, 
15.2, 22.7, and 30.3 µM for 2), 294 nM (for 1) or 196 nM (for 2) of thrombin was added, 
and the fluorescence recovery at 535 nm upon excitation at 485 nm was recorded using a 
fluorescence plate reader. According to the fluorescence recovery, the increases in the 
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fluorescence intensities were converted to the corresponding initial velocities for the 
hydrolysis reactions. The kinetic parameters for thrombin such as Km, Vmax, kcat, and 
kcat/Km were estimated by fitting the data to the Michaelis–Menten equation using the 
least-squares method (Fig. 28).  
 
 
Fig. 28  Michaelis–Menten curve of 1, 2, and 3 catalyzed by thrombin in 50 mM Tris-
HCl buffer (pH 8.0) containing 150 mM NaCl, 1 mM CaCl2, and 0.1 mg/mL BSA at 
room temperature with fluorometric method. Excitation/emission wavelengths were 485 
nm/535 nm for 1–3 and 370 nm/460 nm for 6. 
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The Km value of 1 was 1.6-fold higher than that of 2, which meant that the affinity of 2 
toward thrombin was better than that of 1 (Table 2). The kcat value of 2 was 5-fold higher 
than that of 1. The resulting kcat/Km value of 2 was 10-fold higher than that of 1. Thrombin 
may prefer Val-Pro-Arg-Gly sequence which has an extra glycine at P1′ position to Val-
Pro-Arg because natural substrate for α-thrombin from human such as factor XIII includes 
-Leu-Val-Pro-Arg-Gly- sequence.42,43 The activity of thrombin for 2 was higher than its 
activity for 1 due to the reflection of the specificity of P1′ glycine in 2.  
 
Furthermore, kinetic analysis of 6 was determined for comparison purposes. To each 
concentration of the substrate (1, 2, 4, 10, 16, 24, and 32 µM), 1 nM of thrombin was 
added, and the fluorescence recovery at 460 nm upon excitation at 370 nm was recorded 
using a fluorescence plate reader. While the Km value of 6 was similar to that of 1, the kcat 
value of 6 was dramatically higher than that of 1 and 2. The resulting kcat/Km values 
revealed that the activities of thrombin for 1 and 2 were lower than its activity for standard 
fluorescent substrate 6. 
 
Table 2  Summary of the kinetic parameters of 1, 2, and 6 for thrombin. 
Substrate Km (μM) Vmax (nM·s-1) kcat (s-1) kcat/Km (μM-1·s-1) 
1 12.9 2.49 8.47 x 10-3 6.54 x 10-4 
2 7.93 8.28 4.22 x 10-2 5.32 x 10-3 
6 12.5 8.44 8.44 0.677 
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2.5.7. Molecular simulation 
 
To investigate the cause of difference of kinetic parameters, the simplified molecular 
docking was performed. First, the difference of specificity toward thrombin between 1 
and 6 were surveyed in silico. The three-dimensional structure of D-Phe-Pro-Arg 
chloromethylketone in active site of human α-thrombin (PDB entry: 1PPB) was manually 
modified to those of 1 or 6 by Molecular Operating Environment (MOE) software. The 
structural optimizations near the substrates were performed in MMFF94x force field. In 
the case of 6, it appeared that 6 fitted substrate binding pocket of thrombin (Fig. 29). On 
the other hand, it would seem that 1 did not bind as tightly as 6 because 1 was sterically 
bulkier than 6.  
 
 
Fig. 29  Simulated binding model in the active site of thrombin. The substrates 1 (a) 
and 6 (b) were shown as green ball and stick model. 
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Next, the difference of specificity of self-quenching substrates between trypsin and 
thrombin were also assessed in silico. Comparing the catalytic site of trypsin (PDB entry: 
1PTC) with thrombin (PDB entry: 1PPB) on MOE software, substrate binding pocket of 
thrombin looked more sterically hindered than that of trypsin (Fig. 30). These indicated 
that lower specificity of 1 and 2 for thrombin was ascribed to the bulkiness of self-
quenching substrates and narrower entrance to active site of thrombin. 
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Fig. 30  Active sites in ligand-enzyme complex. The inhibitors of trypsin (a) and 
thrombin (b) were shown as green line model. 
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2.6. Conclusion 
 
In summary, novel self-quenching-based substrates for the detection of trypsin, 
chymotrypsin, and thrombin activities were developed. These substrates can be 
conveniently synthesized by Fmoc SPPS. The results from the fluorescence spectra 
demonstrated that more than 60% of the fluorescence of the substrates was 
advantageously quenched by intramolecular self-quenching and the diminished 
fluorescence was recovered by proteolytic cleavage. The activities of trypsin for 1 and 2 
were almost comparable to that of 6, the standard fluorescent probe. The substrates 1 and 
2 enabled the detection of trypsin at concentrations as low as 111 pM. Inhibitor evaluation 
of BBI revealed that this assay could be applied to inhibitor screening and be used to 
determine not only IC50 but also Ki values. Moreover, kinetic assays for the detection of 
chymotrypsin activity using 3 indicated that our self-quenching-based substrates could be 
applicable for the detection of other disease-related protease activities and inhibitor 
screening. Although in thrombin assay by using 1 and 2, P1′ amino acid could be reflected 
in the kinetic parameters, the activity of thrombin for 1 and 2 was lower than its activity 
for 6 due to the bulkiness of the self-quenching substrates and sterically hindered entrance 
to active site of thrombin according to the simple molecular docking with MOE software. 
 
 
 
 
70 
 
2.7. References 
 
1. Packard, B. Z.; Toptygin, D. D.; Komoriya, A.; Brand, L. Profluorescent protease 
substrates: intramolecular dimers described by the exciton model. Proc. Natl. Acad. 
Sci. USA 1996, 93(21), 11640−11645. 
2. Ternon, M.; Díaz-Mochon, J. J.; Belsom, A.; Bradley, M. Dendrimers and 
combinatorial chemistry—tools for fluorescent enhancement in protease assays. 
Tetrahedron 2004, 60(39), 8721−8728. 
3. Galande, A. K.; Hilderbrand, S. A.; Weissleder, R.; Tung, C. Enzyme-targeted 
fluorescent imaging probes on a multiple antigenic peptide core. J. Med. Chem. 2006, 
49(15), 4715−4720. 
4. Avlonitis, N.; Debunne, M.; Aslam, T.; McDonald, N.; Haslett, C.; Dhaliwal, K.; 
Bradley, M. Highly specific, multi-branched fluorescent reporters for analysis of 
human neutrophil elastase. Org. Biomol. Chem. 2013, 11(26), 4414−4418. 
5. Cera, E. D. Thrombin. Mol. Aspects Med. 2008, 29(4), 203−254. 
6. Crawley, J. T. B.; Zanardelli, S.; Chion, C. K. N. K.; Lane, D. A. The central role of 
thrombin in hemostasis. J. Thromb. Haemost. 2007, 5(s1), 95−101. 
7. Krishnaswamy, S.; Mann, K. G.; Nesheim, M. E. The prothrombinase-catalyzed 
activation of prothrombin proceeds through the intermediate meizothrombin in an 
ordered, sequential reaction. J. Biol. Chem. 1986, 261(19), 8977−8984. 
8. Walker, R. K.; Krishnaswamy, S. The activation of prothrombin by the 
prothrombinase complex: the contribution of the substrate-membrane interaction to 
catalysis. J. Biol. Chem. 1994, 269(44), 27441−27450. 
71 
 
9. Krishnaswamy, S. Exosite-driven substrate specificity and function in coagulation. J. 
Thromb. Haemost. 2005, 3(1), 54−67. 
10. Weisel, J. W. Fibrin assembly: lateral aggregation and the role of the two pairs of 
fibrinopeptides. Biophys. J. 1986, 50(6), 1079−1093. 
11. Wolberg, A. S. Thrombin generation and fibrin clot structure. Blood Rev. 2007, 21(3), 
131−142. 
12. Fenton, J. W.; Fasco, M. J.; Stackrow, A. B. Human thrombins: production, 
evaluation, and properties of α-thrombin J. Biol. Chem. 1977, 252(11), 3587−3598. 
13. Oliver, J. A.; Monroe, D. M.; Roberts, H. R.; Hoffman, M. Thrombin activates factor 
XI on activated platelets in the absence of factor XII. Arterioscler. Thromb. Vasc. 
Biol. 1999, 19(1), 170−177. 
14. Alquwaizani, M.; Buckley, L.; Adams, C.; Fanikos, J. Anticoagulants: a review of 
the pharmacology, dosing, and complications. Curr. Emerg. Hosp. Med. Rep. 2013, 
1(2), 83−97. 
15. Borissoff, J. I.; Spronk, H. M. H.; Heeneman, S.; Cate, H. Is thrombin a key player 
in the ‘coagulation-atherogenesis’ maze? Cardiovasc. Res. 2009, 82(3), 392−403. 
16. Brummel-Ziedins, K. E.; Vossen, C. Y.; Butenas, S.; Mann, K. G.; Rosendaal, F. R. 
Thrombin generation profiles in deep venous thrombosis. J. Thromb. Haemost. 2005, 
3(11), 2497−2505. 
17. Popović, M.; Smiljanić, K.; Dobutović, B.; Syrovets, T.; Simmet, T.; Isenović, E. R. 
Thrombin and vascular inflammation. Mol. Cell. Biochem. 2012, 359(1-2), 301−313. 
72 
 
18. Davalos, D.; Baeten, K. M.; Whitney, M.A.; Mullins, E. S.; Friedman, B.; Olson, E. 
S.; Ryu, J. K.; Smirnoff, D. S.; Petersen, M. A.; Bedard, C.; Degen, J. L.; Tsien, R. 
Y.; Akassoglou, K. Early detection of thrombin activity in neuroinflammatory 
disease. Ann. Neurol. 2014, 75(2), 303−308. 
19. Deng, B.; Lin, Y.; Wang, C.; Li, F.; Wang, Z.; Zhang, H.; Li, X. F.; Le, X. C. Aptamer 
binding assays for proteins: the thrombin example—a review. Anal. Chim. Acta 2014, 
837, 1−15. 
20. Kitamoto, Y.; Imamura, T.; Fukui, H.; Tomita, K. Role of thrombin in mesangial 
proliferative glomerulonephritis. Kidney Int. 1998, 54(5), 1767−1768. 
21. Kitamoto, Y.; Arizono, K.; Fukui, H.; Tomita, K.; Kitamura, H.; Taguma, Y.; 
Imamura, T. Urinary thrombin: a novel marker of glomerular inflammation for the 
diagnosis of crescentic glomerulonephritis (prospective observational study). PLoS 
ONE 2015, 10(3), e0118704. 
22. Hedstrom, L. Serine protease mechanism and specificity. Chem. Rev. 2002, 102(12), 
450−4524. 
23. Cera, E. D. Serine proteases. IUBMB Life 2009, 61(5), 510−515. 
24. Hirota, M.; Ohmuraya, M.; Baba, H. The role of trypsin, trypsin inhibitor, and trypsin 
receptor in the onset and aggravation of pancreatitis. J. Gastroenterol. 2006, 41(9), 
832−836. 
25. Pepeliaev, S.; Krahulec, J.; Černý, Z.; Jílková, J.; Tlustá, M.; Dostálová, J. High level 
expression of human enteropeptidase light chain in Pichia pastoris. J. Biotechnol. 
2011, 156(1), 67−75. 
73 
 
26. Artigas, J. M. G.; Garcia, M. E.; Faure, M. R. A.; Gimeno, A. M. B. Serum trypsin 
levels in acute pancreatic and non-pancreatic abdominal conditions. Postgrad. Med. 
J. 1981, 57(666), 219−222. 
27. Rinderknecht, H. Activation of pancreatic zymogens: normal activation, premature 
intrapancreatic activation, protective mechanisms against inappropriate activation. 
Dig. Dis. Sci. 1986, 31(3), 314−321. 
28. Lankisch, P. G.; Burchard-Reckert, S.; Lehnick, D. Underestimation of acute 
pancreatitis: patients with only a small increase in amylase/lipase levels can also have 
or develop severe acute pancreatitis. Gut. 1999, 44(4), 542−544. 
29. Byrne, M. F.; Mitchell, R. M.; Stiffler, H.; Jowell, P. S.; Branch, M. S.; Pappas, T. 
N.; Tyler, D.; Baillie, J. Extensive investigation of patients with mild elevations of 
serum amylase and/or lipase is ‘low yield’. Can. J. Gastroenterol. 2002, 16(12), 
849−854. 
30. Gaber, A.; Johansson, M.; Stenman, U. H.; Hotakainen, K.; Pontén, F.; Glimelius, 
B.; Bjartell, A.; Jirström, K.; Birgisson, H. High expression of tumour-associated 
trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal 
cancer. Br. J. Cancer 2009, 100(10), 1540−1548. 
31. Wu, L.; Yang, S. H.; Xiong, H.; Yang, J. Q.; Guo, J.; Yang, W. C.; Yang, G. F. 
Nonpeptide-based small-molecule probe for fluorogenic and chromogenic detection 
of chymotrypsin. Anal. Chem. 2017, 89(6), 3687−3693. 
32. Lefkowitz, R. B.; Schmid-Schönbein, G. W.; Heller, M. J. Whole blood assay for 
elastase, chymotrypsin, matrix metalloproteinase-2, and matrix metalloproteinase-9 
activity. Anal. Chem. 2010, 82(19), 8251−8258. 
74 
 
33. Azarkan, M.; Dibiani, R.; Goormaghtigh, E.; Raussens, V.; Baeyens-Volant, D. The 
papaya Kunitz-type trypsin inhibitor is a highly stable β-sheet glycoprotein. Biochim. 
Biophys. Acta 2006, 1764(6), 1063−1072. 
34. Kozlova, N. O.; Bruskovskaya, I. B.; Melik-Nubarov, N. S.; Yaroslavov, A. A.; 
Kabanov, V. A. Catalytic properties and conformation of hydrophobized α-
chymotrypsin incorporated into a bilayer lipid membrane. FEBS Lett. 1999, 461(3), 
141−144. 
35. Winquist, J.; Geschwindner, S.; Xue, Y.; Gustavsson, L.; Musil, D.; Deinum, J.; 
Danielson, U. H. Identification of structural-kinetic and structural-thermodynamic 
relationships for thrombin inhibitors. Biochemistry 2013, 52(4), 613−626. 
36. Frattali, V. Soybean inhibitors: III. Properties of a low molecular weight soybean 
proteinase inhibitor. J. Biol. Chem. 1969, 244(2), 274−280. 
37. Dwivedi, A. K.; Iyer, P. K. A fluorescence turn on trypsin assay based on aqueous 
polyfluorene. J. Mater. Chem. B 2013, 1(32), 4005−4010. 
38. O’Connor, M.; Lee, C.; Ellens, H.; Bentz, J. A novel application of t-statistics to 
objectively assess the quality of IC50 fits for P-glycoprotein and other transporters. 
Pharma. Res. Per. 2014, 3(1), e00078. 
39. Morrison, J. F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by 
tight-binding inhibitors. Biochim. Biophys. Acta 1969, 185(2), 269−286. 
40. Cer, R. Z.; Mudunuri, U.; Stephens, R.; Lebeda, F. J. IC50-to-Ki: a web-based tool for 
converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. 
Nucleic Acids Res. 2009, 37, W441−W445. 
75 
 
41. Souza, L. C.; Camargo, R.; Demasi, M.; Santana, J. M.; Sá, C. M.; Freitas, S. M. 
Effects of an anticarcinogenic Bowman-Birk protease inhibitor on purified 20S 
proteasome and MCF-7 breast cancer cells. PLoS One 2014, 9(1), e86600. 
42. Gallwitz, M.; Enoksson, M.; Thorpe, M.; Hellman, L. The extended cleavage 
specificity of human thrombin. PLoS ONE 2012, 7(2), e31756. 
43. Chang, J. Y. Thrombin specificity: requirement for apolar amino acids adjacent to 
the thrombin cleavage site of polypeptide substrate. Eur. J. Biochem. 1985, 151(2), 
217−224. 
  
76 
 
Chapter 3 
 
Novel bispyrenyl substrates for detection of thrombin and trypsin 
activities 
 
3.1. Introduction 
 
In prior chapter, we referred to the development of novel self-quenching-based substrates 
for protease assay. These substrates have the potential for easily synthesizable, 
inexpensive, and sensitive fluorescent probes for protease assay. However these 
substrates showed insufficient self-quenching efficiency (more than 60%), indicating low 
signal-to-noise (S/N) ratio. According to these findings, the fluorescence switch system 
of the self-quenching-based substrates which uses the change in single wavelength of the 
fluorophore was altered to a dual emission system. The system exploits shift between two 
characteristic wavelengths of the fluorophores. To establish the switch system of emission 
wavelength shift, we focused on pyrene as a fluorophore. 
 
Pyrene has been exploited for the detection and imaging of protein and nucleic acid 
targets because pyrene has two unique fluorescence characteristics, which display an 
monomer fluorescence emission peaks (370−420 nm) and an excimer band (450−550 nm) 
when two pyrene molecules are spatially proximal (~10 Å) (Fig. 1).1,2 
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Fig. 1  Excimer formation by pyrene.3 
 
Pyrene excimer emission, which can be easily observed by naked eyes, donates large 
Stokes shifts (∼130 nm) and long fluorescence lifetimes (∼40 ns).4,5 However, the 
advantages of pyrene monomer/excimer signaling have been rarely exploited for the 
detection of protease activity.6,7  
 
Recently, a few exactly controlled aggregation and dissociation systems of pyrenyl 
compounds have been used for protease assays. Xu et al. reported that electrostatic 
interaction of negatively charged N-[4-(1-pyrenyl)butanoyl]-L-tryptophan with positively 
charged melittin was taken advantage of for the detection of trypsin activity.8 Tang et al. 
developed sodium 3-(pyren-1-yloxy)propane-1-sulfonate (PyOPS)-protamine complex 
for the detection of trypsin activity.9 This complex emits excimer fluorescence due to the 
electrostatic interaction between anionic sulfonic acid of PyOPS and cationic Arg 
residues of protamine in which Arg residues accounts for approximately 67% of contents. 
Cleavage of the protamine by trypsin leads to diminished excimer emission, allowing the 
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detection of trypsin activity. In addition, Wang et al. designed a pyrene-functionalized 
peptidic inhibitor which contains two Pyrene-Lys-Trp-Lys attached via the C-terminus to 
a lysine amide as a branched unit.10 This cationic peptide is allowed to bind to the 
negatively charged surface of β-tryptase, and this non-covalently binding changes 
monomer/excimer signal of pyrene moieties due to aggregation-induced emission (AIE). 
In those systems, assembly and disassembly of pyrenyl compound by intermolecular 
electrostatic interaction lead to the transition of pyrene monomer/excimer emission, 
which enables the detection of protease activity. However, the sensitivity of these sensing 
manner can be scarcely regulated since it depends on the responses of the formation and 
dissolution of the entire assembly of pyrene complexes.11 Moreover, the kinetic assay is 
complicated in these system. 
 
Instead of these intermolecular interaction systems, intramolecular excimer forming 
substrates were also developed. Ahn et al. developed two pyrene-labelled peptide 
substrates which contain two pyrene moieties incorporated into the N- and C-terminus of 
the substrate peptide for trypsin.12  
 
Although several protease probes using pyrene have been reported as noted above, the 
applications of intramolecular pyrene monomer/excimer signaling to the detection of 
protease activity are still rare, and further investigations such as the determination of 
detection limit and inhibitor evaluation using these substrates were not reported. 
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3.2. Design 
 
In this study, we designed and synthesized pyrene monomer/excimer-based peptide 
substrates for the detection of trypsin and thrombin activities. They are composed of two 
1-pyrenebutyric acid (Pba) and one or two substrate peptides for trypsin and thrombin. 
Two types of substrates were designed: long-type substrates and short-type substrate. The 
long-type substrates 1, 2, 3, and 4 are comprised of two corresponding Pba-linked 
substrate peptides on both edges of a core (Fig. 2). The short-type substrate 5 is comprised 
of one corresponding Pba-linked substrate peptide and Pba on each edge of the core 
respectively. These substrates include hexamethylenediamine as the core. Considering 
the effect of sterically hindered pyrene molecule, β-alanine was inserted between the Pba 
and valine residue in 1, 3, and 5. Moreover, one extra amino acid, glycine was also 
inserted between the arginine residue and core in 1, 2, and 5 to demonstrate that the 
specificity of the P1′ amino acid residue can be reflected in the artificial substrate. 
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Fig. 2  Design of the long-type bispyrenyl substrates 1, 2, 3, and 4. 
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Fig. 3 Design of the short-type bispyrenyl substrate 5. 
 
Proximate two pyrene moieties form excited-state dimers in the substrates, and the 
substrates emit excimer fluorescence (Fig. 4). After proteolytic cleavage, these pyrene 
excimer formations dissociate, and the excimer fluorescence decreased as the monomer 
fluorescence increases. Hence, the change of excimer fluorescence enables to detect 
protease activity. 
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Fig. 4  Schematic representation of the detection system for 1. 
 
For the synthesis of long-type substrates, corresponding protected Pba-peptides which 
were synthesized by standard Fmoc solid-phase peptide synthesis (Fmoc SPPS) were 
coupled with both edges of hexamethylenediamine, followed by the deprotection of Pbf 
or Pmc groups. For the synthesis of short-type substrate, N-Boc-hexamethylenediamine 
was coupled with Pba. After the deprotection of Boc group from the previously obtained 
compound, Pba-β-Ala-L-Val-L-Pro-L-Arg(Pbf)-Gly-OH synthesized by Fmoc SPPS was 
then linked. Finally, Pbf group was deprotected. 
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3.3. Experimental section 
 
3.3.1. Materials and instruments 
 
All Fmoc-protected amino acids, Cl-Trt(2-Cl) resin, piperidine, O-(1H-benzotriazol-1-
yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), 1-hydrolxy-1H-
benzotriazole hydrate (HOBt·H2O), N,N-diisopropylethylamine (DIEA), trifluoroethanol, 
2,2,2-trifluoroacetic acid (TFA), and 4 M HCl/Dioxane were purchased from Watanabe 
Chemical Industries, Ltd. α-Trypsin from bovine pancreas, α-chymotrypsin from bovine 
pancreas, thrombin from human plasma, and Bowman-Birk inhibitor from Glycine max 
(soybean) were obtained from Sigma-Aldrich Co. LLC. All solvents and other reagents 
were ordered from Wako Pure Chemical Industries, Ltd. The assay buffer solution was 
50 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl, 1 mM CaCl2, and 0.02% 
(w/v) PEG6000. Analytical high performance liquid chromatography (HPLC) was 
performed on a Hitachi L-7100 instrument equipped with a chromolith performance RP-
18e column (4.6 x 100 mm; Merck). The mobile phases were 0.1% TFA in H2O (solvent 
A) and 0.1% TFA in H2O (solvent B) using a linear gradient of solvent B in solvent A 
(0–100% over 15 min) with a flow rate of 2.0 mL/min, and absorbance at 220 nm was 
used for the detection. Gel filtration chromatography was performed using Sephadex LH-
20 eluting with DMF. Electrospray ionization time-of-flight mass spectrometer (ESI-
TOF-MS) data were measured on a JEOL THE ACCUTOF LC-PLUS JMS-T100LP 
instrument. Fast atom bombardment (FAB)-MS spectra were measured on a JEOL JMS-
SX 102A instrument. pH measurements were made with a D-71 LAQUA portable pH 
meter (Horiba). Absorbance was measured using a GE Healthcare Ultrospec 3300 pro 
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UV/Vis spectrometer or a JASCO V-550 UV/VIS spectrophotometer. Fluorescence 
spectra and enzyme reaction were measured on a JASCO FP-6600 spectrofluorometer. 
Deionized water was obtained from a Milli-Q Plus system (Millipore). 
 
3.3.2. Synthesis 
 
3.3.2.1. Solid-phase synthesis of different sequences of protected pyrenyl 
peptides 
 
The first Fmoc-protected amino acid was loaded onto Cl-Trt(2-Cl) resin. Corresponding 
peptide chains were elongated using Fmoc/piperidine strategies. HBTU and HOBt·H2O 
were used as activating agents. Subsequently, Pba was coupled to the elongated peptides 
in the presence of HBTU, HOBt·H2O, and DIEA. The resin-supported peptides were 
cleaved from the resin in the cleavage cocktail (AcOH/DCM/Trifluoroethanol = 1:3:1). 
The peptides were precipitated by ether in an ice bath, and purified by gel filtration 
chromatography. The purified peptides were analyzed by HPLC and FAB-MS (data not 
shown). 
 
3.3.2.2. Synthesis of 1 
 
To Pba-β-Ala-L-Val-L-Pro-L-Arg(Pbf)-Gly-OH (0.306 g, 0.30 mmol, 2.5 equiv) in 10 
mL of DMF, hexamethylenediamine (0.0016 mL, 0.12 mmol, 1.0 equiv), HBTU (0.114 
g, 0.30 mmol, 2.5 equiv), HOBt·H2O (0.046 g, 0.30 mmol, 2.5 equiv), and DIEA (0.053 
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mL, 0.30 mmol, 2.5 equiv) were added, and the reaction mixture was then stirred at room 
temperature overnight. Evaporated reaction mixture was dissolved in small amount of 
DMF, and purified by gel filtration chromatography. The purified compound (0.050 g, 
0.025 mmol) was dissolved in 10 mL of the deprotection cocktail 
(TFA/Triisopropylsilane/H2O = 95:2.5:2.5), and the reaction mixture was then stirred for 
4 hours at room temperature. The peptide was precipitated by ether in an ice bath. The 
substrate 1 was obtained with 60% yield (0.040 g, 0.022 mmol), and analyzed by HPLC 
and HR-MS (ESI-TOF-MS). 
m/z calcd. for [(M+H)+] C88H117N18O12: 1617.90983; found: 1617.91845, Retention time: 
7.54 min. 
 
 
Fig. 5  HPLC profile of 1. HPLC conditions: a linear gradient of solvent B in solvent 
A (0–100% over 15 min); Chromolith performance RP-18e column (4.6 x 100 mm; 
Merck); flow rate, 2 mL/min; solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in 
CH3CN; detection at 220 nm. 
 
 
Fig. 6  MASS spectrum of 1. 
7.54 min 
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3.3.2.3. Synthesis of 2 
 
To Pba-L-Val-L-Pro-L-Arg(Pbf)-Gly-OH (0.285 g, 0.30 mmol, 2.5 equiv) in 10 mL of 
DMF, hexamethylenediamine (0.016 mL, 0.12 mmol, 1.0 equiv), HBTU (0.114 g, 0.30 
mmol, 2.5 equiv), HOBt·H2O (0.046 g, 0.30 mmol, 2.5 equiv), and DIEA (0.053 mL, 
0.30 mmol, 2.5 equiv) were added, and the reaction mixture was then stirred at room 
temperature overnight. Evaporated reaction mixture was dissolved in small amount of 
DMF, and purified by gel filtration chromatography. The purified compound (0.050 g, 
0.025 mmol) was dissolved in 10 mL of the deprotection cocktail 
(TFA/Triisopropylsilane/H2O = 95:2.5:2.5), and the reaction mixture was then stirred for 
4 hours at room temperature. The peptide was precipitated by ether in an ice bath. The 
substrate 2 was obtained with 34% yield (0.037 g, 0.022 mmol), and analyzed by HPLC 
and HR-MS (ESI-TOF-MS). 
m/z calcd. for [(M+H)+] C82H107N16O10: 1475.83561; found: 1475.82969, Retention time: 
7.80 min.  
 
 
Fig. 7  HPLC profile of 2. HPLC conditions: a linear gradient of solvent B in solvent 
A (0–100% over 15 min); Chromolith performance RP-18e column (4.6 x 100 mm; 
Merck); flow rate, 2 mL/min; solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in 
CH3CN; detection at 220 nm. 
 
7.80 min 
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Fig. 8  MASS spectrum of 2. 
 
3.3.2.4. Synthesis of 3 
 
To Pba-β-Ala-L-Val-L-Pro-L-Arg(Pmc)-OH (0.372 g, 0.38 mmol, 2.5 equiv) in 10 mL of 
DMF, hexamethylenediamine (0.0019 mL, 0.15 mmol, 1.0 equiv), HBTU (0.144 g, 0.38 
mmol, 2.5 equiv), HOBt·H2O (0.058 g, 0.38 mmol, 2.5 equiv), and DIEA (0.066 mL, 
0.38 mmol, 2.5 equiv) were added, and the reaction mixture was then stirred at room 
temperature overnight. Evaporated reaction mixture was dissolved in small amount of 
DMF, and purified by gel filtration chromatography. The purified compound (0.060 g, 
0.029 mmol) was dissolved in 10 mL of the deprotection cocktail 
(TFA/Triisopropylsilane/H2O = 95:2.5:2.5), and the reaction mixture was then stirred for 
4 hours at room temperature. The peptide was precipitated by ether in an ice bath. The 
substrate 3 was obtained with 52% yield (0.040 g, 0.023 mmol), and analyzed by HPLC 
and HR-MS (ESI-TOF-MS). 
m/z calcd. for [(M+H)+] C84H111N16O10: 1503.86691; found: 1503.86824, Retention time: 
7.26 min.  
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Fig. 9  HPLC profile of 3. HPLC conditions: a linear gradient of solvent B in solvent 
A (0–100% over 15 min); Chromolith performance RP-18e column (4.6 x 100 mm; 
Merck); flow rate, 2 mL/min; solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in 
CH3CN; detection at 220 nm. 
 
 
Fig. 10  MASS spectrum of 3. 
 
3.3.2.5. Synthesis of 4 
 
To Pba-L-Val-L-Pro-L-Arg(Pbf)-OH (0.268 g, 0.30 mmol, 2.5 equiv) in 10 mL of DMF, 
hexamethylenediamine (0.016 mL, 0.12 mmol, 1.0 equiv), HBTU (0.114 g, 0.30 mmol, 
2.5 equiv), HOBt·H2O (0.046 g, 0.30 mmol, 2.5 equiv), and DIEA (0.053 mL, 0.30 mmol, 
2.5 equiv) were added, and the reaction mixture was then stirred at room temperature 
overnight. Evaporated reaction mixture was dissolved in small amount of DMF, and 
purified by gel filtration chromatography. The purified compound (0.050 g, 0.027 mmol) 
was dissolved in 10 mL of the deprotection cocktail (TFA/Triisopropylsilane/H2O = 
95:2.5:2.5), and the reaction mixture was then stirred for 4 hours at room temperature. 
7.26 min 
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The peptide was precipitated by ether in an ice bath. The substrate 4 was obtained with 
29% yield (0.037 g, 0.023 mmol), and analyzed by HPLC and HR-MS (ESI-TOF-MS). 
m/z calcd. for [(M+H)+] C78H101N14O8: 1361.79268; found: 1361.78771, Retention time: 
7.96 min.  
 
 
Fig. 11  HPLC profile of 4. HPLC conditions: a linear gradient of solvent B in solvent 
A (0–100% over 15 min); Chromolith performance RP-18e column (4.6 x 100 mm; 
Merck); flow rate, 2 mL/min; solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in 
CH3CN; detection at 220 nm. 
 
 
Fig. 12  MASS spectrum of 4.  
 
 
 
 
 
7.96 min 
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3.3.2.6. Synthesis of 5 
 
3.3.2.6.1. Synthesis of Boc-HN-(CH2)6-NH-Pba 
 
N-Boc-hexamethylenediamine hydrochloride (0.506 g, 2.0 mmol, 1.0 equiv) was 
dissolved in 10 mL of DMF using an ice bath to cool down, Pba (0.577 g, 2.0 mmol, 1.0 
equiv), HBTU (0.910 g, 2.4 mmol, 1.2 equiv), HOBt·H2O (0.368 g, 2.4 mmol, 1.2 equiv), 
DIEA (0.42 mL, 2.4 mmol, 1.2 equiv) were added to the solution. The reaction mixture 
was stirred at room temperature overnight. The mixture was concentrated, and the desired 
compound was crystallized by ether in an ice bath. The pure compound was obtained with 
82% yield (0.820 g, 1.7 mmol), and analyzed by HPLC and ESI-TOF-MS (HPLC profile 
and MASS spectrum not shown). 
m/z calcd. for [(M+Na)+] C31H38N2NaO3: 509.28; found: 509.25, Retention time: 6.54 
min. 
 
3.3.2.6.2. Synthesis of H2N-(CH2)6-NH-Pba·HCl 
 
The suspension of Boc-HN-(CH2)6-NH-Pba (0.500 g, 1.0 mmol, 1.0 equiv) in 4 M 
HCl/Dioxane was incubated for 2 hours in an ice bath. The suspension was concentrated, 
and desired compound was crystallized by ether in an ice bath. The pure compound was 
obtained with over 100% yield (0.454 g, 1.1 mmol), and analyzed by HPLC (HPLC 
profile not shown). 
Retention time: 5.01 min. 
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3.3.2.6.3. Synthesis of 5 
 
H2N-(CH2)6-NH-Pba·HCl (0.085 g, 0.20 mmol, 1.0 equiv) and Pba-β-Ala-L-Val-L-Pro-
L-Arg(Pbf)-Gly-OH (0.163 g, 0.16 mmol, 0.8 equiv) were dissolved in 10 mL of DMF in 
an ice bath. HBTU (0.091 g, 0.24 mmol, 1.2 equiv), HOBt·H2O (0.037 g, 0.24 mmol, 1.2 
equiv), and DIEA (0.075 mL, 0.44 mmol, 2.2 equiv) were added to the solution, and the 
reaction mixture was then stirred at room temperature overnight. Evaporated reaction 
mixture was dissolved in small amount of DMF, and purified by gel filtration 
chromatography. The purified compound (0.020 g, 0.014 mmol) was dissolved in 10 mL 
of the deprotection cocktail (TFA/Triisopropylsilane/H2O = 95:2.5:2.5), and the reaction 
mixture was then stirred for 4 hours at room temperature. The peptide was precipitated 
by ether in an ice bath. The substrate 5 was obtained with 22% yield (0.040 g, 0.022 
mmol), and analyzed by HPLC and HR-MS (ESI-TOF-MS). 
m/z calcd. for [(M+H)+] C67H81N10O7: 1137.62897; found: 1137.62864, Retention time: 
8.36 min. 
 
 
Fig. 13  HPLC profile of 5. HPLC conditions: a linear gradient of solvent B in solvent 
A (0–100% over 15 min); Chromolith performance RP-18e column (4.6 x 100 mm; 
Merck); flow rate, 2 mL/min; solvent A: 0.1% TFA in H2O; solvent B: 0.1% TFA in 
CH3CN; detection at 220 nm. 
 
8.36 min 
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Fig. 14  MASS spectrum of 5. 
 
3.3.3. Analysis 
 
3.3.3.1. Preparation of stock solutions 
 
The stock solutions of 1, 2, 3, 4, 5, and Pba were prepared in dimethylsulfoxide (DMSO) 
and stored in a refrigerator. The concentration of the pyrene solutions was determined by 
the molar extinction coefficient of Pba in DMF at 344 nm (ε344 in DMF = 35,100 M-1·cm-
1). The stock solution of trypsin and thrombin in the micromolar range was prepared in 
the buffer and stored in a freezer. The concentration of the trypsin solution was 
determined using the molar extinction coefficient of trypsin at 280 nm (ε280 = 36,280 M-
1·cm-1).13 The concentration of the thrombin solution was determined using the molar 
extinction coefficient of thrombin at 280 nm (ε280 = 66,800 M-1·cm-1).14 The stock 
solution of Bowman–Birk inhibitor (BBI) in the micromolar range was prepared in 
distilled water and stored in a freezer. The concentration of BBI was estimated 
spectrophotometrically using the values of Mr = 7,975 Da and A1%280 = 4.4.15 
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3.3.3.2. Investigation of monomer and excimer emission 
 
In the case of spectral survey, the stock solutions of 1, 2, 3, 4, 5, and Pba were diluted 
with DMSO, and an equimolar solution of each of the pyrene moieties (4 µM) was 
prepared. The fluorescence spectra of these solutions upon excitation at 344 nm were 
measured with a spectrofluorometer. 
 
As for the investigation of kinetic alteration, the stock solution of 1 was diluted with the 
buffer, and the final concentration of 1 was adjusted to 10 µM. The stock solution of 
trypsin was also diluted with the buffer, and the final concentration of trypsin was 
adjusted to 10 nM. The hydrolysis of 1 was initiated by the addition of trypsin solution, 
and monitored fluorometrically by using a spectrofluorometer with an excitation of 344 
nm and an emission of 378 nm for monomer fluorescence or 480 nm for excimer 
fluorescence. 
 
3.3.3.3. Selection of optimum substrate for trypsin 
 
The stock solutions of 1, 2, 3, 4, and 5 were diluted with DMSO and the buffer, and the 
final concentration of these substrates ranged from 2 to 10 µM. The stock solution of 
trypsin was diluted with the buffer, and the final concentration of trypsin was adjusted to 
0.4 nM (for 1), 0.5 nM (for 2), 30 nM (for 3), 40 nM (for 4), and 1.2 nM (for 5) 
respectively. The hydrolysis of the different concentrations of 1, 2, 3, 4, and 5 was 
initiated by the addition of trypsin solution, and monitored fluorometrically by using a 
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spectrofluorometer with an excitation of 344 nm and an emission of 480 nm. The 
concentration of DMSO in the assay was approximately 20%. The kinetic parameters of 
Km, Vmax, kcat, and kcat/Km were calculated by fitting the Lineweaver–Burk plot described 
below with the least-squares method. 
1
𝑣0
=
𝐾m
𝑉max
1
[S]
+
1
𝑉max
 (1) 
𝑘cat =
𝑉max
[E]
 (2) 
where v0 is the initial velocity, [S] is the substrate concentration, Km is the Michaelis 
constant, Vmax is the maximal velocity, [E] is the trypsin concentration, and kcat is the 
turnover number. 
 
3.3.3.4. Kinetic assay of trypsin using optimum substrate 1 
 
The stock solution of 1 was diluted with the buffer, and the final concentration of 1 ranged 
from 2 to 10 µM. The stock solution of trypsin was also diluted with the buffer, and the 
final concentration of trypsin was adjusted to 40 pM. The hydrolysis of the different 
concentrations of 1 was initiated by the addition of trypsin solution, and monitored 
fluorometrically by using a spectrofluorometer with an excitation of 344 nm and an 
emission of 480 nm. The concentration of DMSO in the assay was less than 2%. The 
kinetic parameters of Km, Vmax, kcat, and kcat/Km were calculated by fitting the Michaelis–
Menten equation described below with the least-squares method. 
𝑣0 =
𝑉max[S]
𝐾m + [S]
 (3) 
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where v0 is the initial velocity, [S] is the substrate concentration, Km is the Michaelis 
constant, Vmax is the maximal velocity, [E] is the trypsin concentration, and kcat is the 
turnover number. 
 
3.3.3.5. Determination of detection limit of trypsin activity 
 
The final concentration of 1 was adjusted to 10 µM. The final concentration of trypsin 
ranged from 7.5 to 150 pM. The fluorescence decrease of 1 at 480 nm in the presence of 
different concentrations of trypsin was measured using a spectrofluorometer. The 
detection limit for trypsin was calculated using the following formula:16 
Limit of detection (LOD) =
3𝑠𝑦/𝑥
𝐾
 (4) 
where sy/x is the standard deviation of y-residuals and K is the slope of the linear plot of 
change of the excimer fluorescence intensity versus trypsin concentration. 
 
3.3.3.6. Determination of IC50 and Ki of BBI 
 
The final concentration of 1 was adjusted to 10 µM, and the final concentration of trypsin 
was adjusted to 150 pM. The final concentration of BBI ranged from 0 to 20 nM. 
Hydrolysis reactions for the different concentrations of BBI were initiated by the addition 
of the trypsin solution, and monitored fluorometrically by using a spectrofluorometer as 
mentioned above. The IC50 for BBI was estimated by fitting the Hill equation described 
below with the least-squares method.17 
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Inhibition efficiency (%) = 𝐸bottom +
𝐸top − 𝐸bottom
1 + exp{𝑛(ln IC50 − ln[I])}
 (5) 
where Ebottom is the minimal inhibition efficiency (0%), Etop is the maximal inhibition 
efficiency (100%), n is the Hill constant, and [I] is the BBI concentration. 
 
Subsequently, the Ki for BBI was estimated by fitting the Morrison equation described 
below with the least-squares method.18 
𝑣i
𝑣0
= 1 −
([E] + [I] + 𝐾i) − √([E] + [I] + 𝐾i)2 − 4[E][I]
2[E]
 (6) 
where vi is the initial velocity in the presence of BBI, v0 is the initial velocity in the 
absence of BBI, [E] is the trypsin concentration, [I] is the BBI concentration, and Ki is 
the dissociation constant. 
 
3.3.3.7. Detection of thrombin activity 
 
The stock solution of 1 was diluted with the buffer, and the final concentration of 1 was 
adjusted to 10 µM. The stock solution of thrombin was also diluted with the buffer, and 
the final concentration of thrombin was adjusted to 88.5 nM. The hydrolysis of 1 was 
initiated by the addition of thrombin solution, and monitored fluorometrically by using a 
spectrofluorometer with an excitation of 344 nm and an emission of 480 nm. 
 
 
97 
 
3.4. Results and discussion 
 
3.4.1. Investigation of monomer and excimer emission 
 
Initially, we investigated that the intramolecular excimer emission of synthesized 
substrates was observed. A total of 2 µM of 1–5 were prepared in DMSO. Similarly, 4 
µM of a Pba solution was also prepared in DMSO as a control sample. All of the solutions 
contained 4 µM of the pyrene moieties. The fluorescence spectra upon excitation at 344 
nm of each sample prior to the addition of protease were measured using a 
spectrofluorometer. All substrates exhibited higher excimer fluorescence compared with 
Pba, which indicated that two pyrene moieties in the substrates were spatially proximate 
(Fig. 15). Substrates 5 showed the highest excimer fluorescence owing to its shortest 
peptide unit. The excimer fluorescence of 1 and 2, which was almost equal, was slightly 
higher than that of 3, and 4 had the lowest excimer emission. These indicated that inserted 
β-alanine in the substrates hardly affected the intramolecular excimer formation while 
extra glycine might lead to reduced excimer formation. However, excimer fluorescence 
intensities of 1–4 were not completely dependent on the length of peptide moiety. 
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Fig. 15  Monomer and excimer emission of 1, 2, 3, 4, 5 (2 µM), and Pba (4 µM) in 
DMSO at room temperature. Excitation wavelength was 344 nm. 
 
Then, the change of monomer and excimer emission during tryptic hydrolysis was traced. 
Final concentration of 1 was adjusted to 10 μM, and final concentration of trypsin was 
adjusted to 10 nM with the buffer. To a solution of 1 trypsin was added, and the monomer 
fluorescence intensity at 378 nm or the excimer fluorescence intensity at 480 nm upon 
excitation at 344 nm were recorded respectively. Tryptic cleavage led to the simultaneous 
changes that the monomer emission increased, and the excimer emission decreased (Fig. 
16). These results were consistent with our expected design concept of the bispyrenyl 
substrates. 
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Fig. 16  Kinetic changes in monomer and excimer fluorescence of 1 (10 µM) during 
tryptic hydrolysis (10 nM) in 50 mM Tris-HCl buffer (pH 8.0) containing 150 mM 
NaCl, 1 mM CaCl2, and 0.02% (w/v) PEG6000 at room temperature. Excitation 
wavelength was 344 nm. 
 
3.4.2. Selection of optimum substrate according to kinetic assays of 
trypsin 
 
Next, the decrease in the fluorescence intensity of different concentrations of the 
substrates during tryptic degradation was monitored. To each concentration of the 
substrates (2, 3, 4, 6, 8, and 10 μM), corresponding concentration of trypsin was added, 
and the excimer emission at 480 nm upon excitation at 344 nm was recorded. All of the 
final buffer solutions contained 20% (v/v) DMSO due to poor solubility of 4 and 5. The 
final concentration of trypsin was adjusted to 400 pM (for 1), 500 pM (for 2), 30 nM (for 
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3), 40 nM (for 4), or 1.2 nM (for 5). Subsequently, the kinetic parameters for trypsin were 
calculated. According to the change in excimer fluorescence, the decreases in the 
fluorescence intensities were converted to the corresponding initial velocities for the 
hydrolysis reactions. The kinetic parameters for trypsin activity such as Michaelis 
constant (Km), Maximum reaction rate (Vmax), turnover number (kcat), and specificity 
constant (kcat/Km) were estimated by fitting the data to the Lineweaver–Burk plot using 
the least-squares method (Fig. 17).  
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Fig. 17  Lineweaver–Burk plot of 1 (a), 2 (b), 3 (c), 4 (d), and 5 (e) catalyzed by 
trypsin in 20% DMSO in 50 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl, 1 
mM CaCl2, and 0.02% (w/v) PEG6000 at room temperature with fluorometric method. 
Excitation/emission wavelengths were 344 nm/480 nm. 
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The Km value of 5 was the lowest of that of the other substrates, which meant that the 
affinity of 5 toward trypsin was the highest (Table 1). This was because the retention time 
of 5 from HPLC analysis was the longest, indicating that the 5 had the highest 
hydrophobicity of the other substrates. As a result of the difference of the hydrophobic 
properties, it was expected that the difference of Km values might be observed. Although 
the hydrophobicity of 3 was moderate, Km value of 3 was dramatically high. As for 4, 
modest Km value was calculated, which was lower than that of 1 and 2. In contrast, the 
kcat value of 4 was the lowest of that of other substrates, which indicated that 4 was 
liberated from trypsin with difficulty. Substrates 1 and 2 exhibited higher kcat values since 
the extra glycine provided conformational and hydrophilic benefits for the release of the 
enzyme from the enzyme-substrate complex. The kcat value of 5 was considerably lower 
than that of 1 despite their same peptide sequences. One explanation was that 1 had two 
cleavage sites for trypsin compared with one site in 5. The resulting kcat/Km values of 1 
and 2 were almost equal, and 1.5-fold higher than that of 5. This indicated that extra β-
alanine minimally affected the interaction of 1 and 2 with trypsin, and the number of 
recognition sites influenced substrate specificity. On the other hand, the kcat/Km values of 
3 and 4 were lower than that of the other substrates by far, which indicated that extra 
glycine had great influence on the specificity. Considering these results and solubility of 
the substrates, 1 was picked for the follow-up studies. 
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Table 1  Summary of the kinetic parameters of 1, 2, 3, 4, and 5 for trypsin in the 
presence of 20% DMSO. 
Substrate [E] (nM) Km (μM) Vmax (nM·s-1) kcat (s-1) kcat/Km (μM-1·s-1) 
1 0.4 73.9 15.6 39.1 0.529 
2 0.5 88.3 22.9 45.8 0.518 
3 30 178 50.1 1.67 9.40 x 10-3 
4 40 52.7 21.9 0.546 1.04 x 10-2 
5 1.2 31.2 12.9 10.8 0.345 
 
3.4.3. Kinetic assay of trypsin using selected substrate 1 
 
The kinetic parameters of 1 for trypsin were verified under the condition of negligible 
amount of DMSO in the buffer. The final concentration of 1 was adjusted to 2, 3, 4, 6, 8, 
10 μM with the buffer, and the final concentration of trypsin was adjusted to 40 pM with 
the buffer. DMSO included less than 2% in the reaction mixture. The kinetic parameters 
were estimated by fitting the data to the Michaelis–Menten equation using the least-
squares method (Fig. 18).  
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Fig. 18  Michaelis–Menten curve of 1 catalyzed by trypsin (40 pM) in 50 mM Tris-
HCl buffer (pH 8.0) containing 150 mM NaCl, 1 mM CaCl2, and 0.02% (w/v) PEG6000 
at room temperature with fluorometric method. Excitation/emission wavelengths were 
344 nm/480 nm. 
 
On the basis of the above kinetics, Km, Vmax, kcat, and kcat/Km values were determined to 
be 6.39 μM, 2.00 nM·s-1, 50.0 s-1, and 7.82 μM-1·s-1 respectively. In previous chapter, it 
was stated that Km, Vmax, kcat, and kcat/Km values of trypsin using standard fluorescent 
probe, iBoc-VPR-MCA (6), were determined to be 2.80 μM, 8.04 nM·s-1, 8.04 s-1, and 
2.87 μM-1·s-1 respectively. Comparison of these values clearly demonstrated that 1 was 
an appropriate substrate for measuring trypsin activity. 
 
3.4.4. Determination of detection limit of trypsin 
 
The limit of detection for trypsin using 1 was determined in order to accomplish a 
quantitative assay for trypsin. The concentration of the substrates was fixed at 10 μM, and 
different concentrations of trypsin (7.5, 10, 25, 50, 75, 100, 125, and 150 pM) were 
employed. According to the linear relationship observed between the relative excimer 
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reduction and trypsin concentration, the detection limit for trypsin was calculated (Fig. 
19). A lower limit of 4.11 pM trypsin could catalyze the decrease of excimer fluorescence 
of 1 compared with 30.9 pM trypsin for conventional fluorescent probe 6 described in 
previous chapter. These results clearly demonstrated 1 was preferable for the detection of 
trypsin activity to standard fluorescent probe, Peptide-MCA. 
 
 
Fig. 19  The linear relationship between amounts of change of the fluorescence 
intensity of the substrates (10 µM) within a set time of 20 minutes. Excitation/emission 
wavelengths were 344 nm/480 nm. 
 
3.4.5. Evaluation of trypsin inhibitor 
 
Next, we confirmed whether 1 could be used for inhibitor evaluation. The inhibition of 
trypsin activity by the Bowman–Birk inhibitor (BBI) which is the most commonly used 
trypsin inhibitor was investigated using 1. To 10 μM of 1, different concentrations of BBI 
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(0, 1, 2, 3, 4, 5, 10, 15, and 20 nM) were added, followed by addition of 150 pM of trypsin. 
During tryptic cleavage, excimer emission at 480 nm upon excitation at 344 nm was 
recorded. As expected, the higher the concentration of BBI was present in the reaction 
mixture, the slower the fluorescence decrease was (Fig 20a). After plotting the inhibition 
efficiencies versus the BBI concentrations, the IC50 value was calculated by fitting the 
data to the Hill equation (Fig. 20b). The IC50 value for BBI using 1 as substrate was 
estimated as 8.73 nM. 
 
 
Fig. 20  Plots (a) and fitting curve with Hill equation (b) of inhibition efficiencies of 
BBI toward trypsin (150 pM) with 10 µM of 1. 
 
Because IC50 value depends on enzyme concentration,19 the Ki value for BBI was 
calculated by using the Morrison equation to obtain a more accurate representation of the 
inhibition (Fig. 21). The Ki value determined from the Morrison equation was 9.36 nM. 
The Ki of BBI has been reported to be between 10-7 and 10-9 M,20 and our value fall within 
this range. Therefore, 1 can be used for evaluation of inhibitors of trypsin. 
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Fig. 21  Plots and fitting curve with Morrison equation of inhibition efficiencies of 
BBI toward trypsin (150 pM) with 10 µM of 1. 
 
3.4.6. Detection of thrombin activity 
 
Finally, the decrease in the fluorescence intensity of 1 during thrombin cleavage was 
monitored. Final concentration of 1 was adjusted to 10 μM, and final concentration of 
thrombin was adjusted to 88.5 nM. To a solution of 1 thrombin was added, and the 
excimer emission at 480 nm upon excitation at 344 nm was recorded. The significant but 
relatively slow decrease in excimer fluorescence could be observed (Fig. 22). This slow 
cleavage of thrombin may be caused by the same reasons of self-quenching substrates 
that were the bulkiness of bispyrenyl substrates and narrower entrance to active site of 
thrombin as mentioned in previous chapter. 
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Fig. 22  Kinetic changes in excimer fluorescence of 1 (10 µM) during thrombin 
hydrolysis (88.5 pM) in 50 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl, 1 
mM CaCl2, and 0.02% (w/v) PEG6000 at room temperature. Excitation wavelength was 
344 nm. 
 
3.5. Conclusion 
 
In summary, novel pyrene monomer/excimer-based peptide substrate 1 for the detection 
of trypsin and thrombin activities was developed. The results from the fluorescence 
spectra demonstrated that the significant excimer fluorescence of 1–5 caused by 
intramolecular proximate pyrene moieties was observed, and this fluorescence was 
decreased by tryptic cleavage. The kinetic assays verified that the activity of trypsin for 
1 was higher than that of 6, the standard fluorescent probe. The substrates 1 enabled the 
detection of trypsin at concentrations as low as 4.11 pM which was considerably lower 
than 30.9 pM of 6. Inhibitor evaluation of BBI revealed that this assay could be applied 
to inhibitor screening and be used to determine not only IC50 but also Ki values. However, 
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thrombin activity could not be detected by 1 with adequate sensitivity due to the bulkiness 
of the substrates and sterically hindered entrance to active site of thrombin. 
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Chapter 4 
 
General conclusion 
 
Proteases are some of the most vital physiological enzymes, and have been targeted for 
the development of simple and sensitive assays for disease diagnosis, therapy, and 
biological research. Therefore a variety of techniques for protease assays have been 
developed. 
 
Immunological methods such as western blotting and ELISA are the sensitive techniques 
for the quantitation of the amount of target protease. However, progression and state of 
diseases are directly related to protease activity rather than protease amount, and 
measurement of protease activity is more significant in disease diagnosis, 
pathophysiological research, and drug discovery. In addition, immunological methods 
cannot be used for the evaluation of protease inhibitors. Inhibitor evaluation is essential 
in drug discovery. Besides, these assays are time consuming, and required expensive 
reagents and specific instruments. 
 
Hence, many fluorescent peptide probes such as Peptide-MCA and FRET-based substrate 
have been developed, and are now commercially available. However, commercially 
available Peptide-MCA and FRET-based substrates are not versatile. In the case of an 
AMC-based assay, the specificity for the P1′ amino acid residue (counterpart of the S1′ 
subsite of the protease), which is important for substrate recognition and catalytic 
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efficiency, is not reflected in the artificial substrate. In a FRET-based assay, the 
combination of fluorophores and quenchers can be limiting, and expensive fluorophores 
or quenchers are often required. Furthermore, the synthesis of FRET-based substrates is 
usually complicated because at least one pair of orthogonal protecting groups is needed 
so that the two different dyes required for the FRET are coupled. 
 
To overcome these problems in standard fluorescent probes for protease assays, two types 
of novel doubly labelled fluorescent peptide probes for the detection of protease activity 
using intramolecular interaction between identical fluorophores were developed. 
 
Self-quenching-based substrates, which are consisted of two FITC-linked substrate 
peptides and lysine as a branched unit, were designed, and it is demonstrated that these 
substrates can be easily synthesized by only Fmoc SPPS technique. The substrates 
showed significant quenching by intramolecular self-quenching and the fluorescence 
recovery by proteolytic cleavage. The activities of trypsin for self-quenching substrates 
were almost comparable to that of the standard fluorescent probe, peptide-MCA. The 
substrates enabled the detection of trypsin at concentrations as low as 111 pM, and the 
inhibitor evaluation such as the calculation of IC50 and Ki values was also executed. The 
kinetic assay for thrombin was successfully carried out, and these results indicated that 
the activities of thrombin for the substrates were inferior to that of Peptide-MCA. 
Molecular simulation implied that this lower ability toward thrombin attributed in the 
bulkiness of these substrates and sterically hindered entrance to active site of thrombin. 
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Bispyrenyl substrates, which are consisted of two different lengths of Pba-linked substrate 
peptides and hexamethylenediamine as a core, were successfully designed and 
synthesized. The substrates showed significant excimer emission by intramolecular 
excimer formation of two pyrene moieties and this fluorescence decreased by tryptic 
cleavage. The activity of trypsin for the optimum substrate was higher than that of 
peptide-MCA. The substrate enabled the detection of trypsin activity at concentrations as 
low as 4.11 pM. This detection limit of the substrate was preferable for trypsin assay to 
Peptide-MCA, and was not inferior to those of the immunology-based methods. The 
evaluation of protease inhibitor was successfully performed. In spite of insufficient 
sensitivity for thrombin, the detection of disease-related thrombin activity according to 
the decrease of excimer emission of bispyrenyl substrate could be also executed. 
 
The synthesis of both types of substrates is relatively easy due to incorporation of two 
identical fluorophores. As for the detection of trypsin activity, both types of substrates 
display comparable or higher sensitivity compared with Peptide-MCA. These substrates 
are favorable for exploration of optimum substrate sequence and screening potential 
inhibitor. To our knowledge, our study is the first to demonstrate that the fluorescent 
peptide probes exploiting intramolecular interaction between two identical fluorophores 
such as self-quenching or pyrene excimer formation can be applicable to substrate 
optimization and inhibitor screening. Though the sensitivity for thrombin is not 
satisfactory, these detection mechanisms can be adapted for other protease targets by 
simple change of the peptide sequence. Devoted improvement in the substrate design 
certainly allows usage of these substrates to expand into the detection of other disease-
related protease activity. These intramolecular interaction-based substrates are expected 
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to be useful not only for biological and pathological investigations but also for clinical 
application such as in vitro diagnostic and point of care (POC). 
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